Methods For Improving Skin Quality

ABSTRACT

A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase.

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No.61/295,732, filed Jan. 17, 2010 and U.S. Provisional Application No.61/295,826, filed Jan. 18, 2010.

FIELD OF THE INVENTION

The present invention relates to methods for improving skin quality bydelivering personal care articles that provide a premium product usageexperience for the consumer and skin benefits that persist beyond theapplication.

BACKGROUND OF THE INVENTION

Personal care articles are well known and widely used on hair and skinfor delivering actives that provide, for example, one or more benefitsof cleansing, moisturizing, hiding or reducing imperfections, reducingoiliness, and providing scent to either or both the shower and the hairor skin. The efficacy of personal care compositions for cleaning andmoisturizing, particularly with respect to reliving skin dryness andsigns of aging, is directly related to the frequency of use and thelevel of benefit materials. And the pleasurable experience of usingpersonal care compositions, particularly for the benefits of latheringand scenting, are similarly related to the frequency of use and thelevel of benefit materials in the personal care article.

Consumers typically have limited space to accommodate an extensiveselection of personal care articles, hence they seek products thatdeliver the maximum benefits and pleasurable experience during use. If atreatment regime contains too many steps or too many packages, consumersoften tire of the regime of personal care compositions over time.Likewise, if a personal care article contains a balance of actives thatare perceived by consumers to provide an overall non-pleasurable usageexperience, the consumers lose interest in using the product. As aresult, in either case, consumer may decrease, suspend, or even orabandon use of the personal care article despite what may be significantbenefits gained by the continued compliant use over time.

The methods of the present invention fulfill this need for a simplifiedregime that provides excellent skin benefits.

SUMMARY OF THE INVENTION

The present invention is directed to methods and regimens forapplication of a rinse-off personal care product for treating andmaintaining the quality of skin and to minimize the signs of aging.Thus, in various embodiments, provided are skin treatment regimens thatcomprise applying to the skin of a user a composition formulated tocomprise varying ratios of lathering agent to hydrophobic benefit agent,said varying ratios being either continuous or discrete in a treatmentcycle comprising at least first and second phases. The compositionapplied during the first phase comprises a first of the varying ratios,and the composition applied during the second phase comprises a secondof the varying ratios. In some embodiments, said second ratio is lowerthan the first ratio. In some embodiments, the treatment cycle comprisesa third phase, and the composition applied therein comprises a third ofthe varying ratios. In some embodiments, said third ratio higher thanthe second ratio. In some embodiments, the composition is provided tothe user through a delivery article adapted to dispense the compositionin discrete aliquots of approximately equal volume.

The present invention is also directed to method of identifying andproviding personal care products that are suitable for treating andmaintaining the quality of skin. In some aspects the methods aredirected to optimizing personal care products for specific populationsof users.

The present invention is also directed to compositions and methods forassessing, treating and maintaining the quality of skin and minimizingthe signs of aging by assessing the activity of one more skin biomarkersthat are indicative of skin quality.

The regimens and methods of the present invention can be practiced usingpersonal care articles for dispensing a personal care composition asdisclosed herein. The disclosed personal care article comprises a singlechamber package and a personal care article. The single chamber packagecomprises a dispensing orifice, a first zone proximal to the dispensingorifice, a second zone medial to the dispensing orifice, and a thirdzone distal to the dispensing orifice. The personal care articlecomprises a first personal care composition, a second personal carecomposition and a third personal care composition. The first personalcare composition is substantially within the first zone and comprises afirst concentration of a hydrophobic benefit material. The secondpersonal care composition is substantially within the second zone andcomprises a second concentration of a hydrophobic benefit material. Thethird personal care composition is substantially within the third zoneand comprises a third concentration of a hydrophobic benefit material.The second concentration is greater than the first concentration and thethird concentration of the hydrophobic benefit material.

In another aspect of the present invention, the first concentrationcomprises from about 15% to less than 35%, by weight of the firstpersonal care composition, of hydrophobic benefit material, the secondconcentration comprises from about 35% to about 65%, by weight of thesecond personal care composition, of hydrophobic benefit material, andthe third concentration comprises from about 15% to less than 35%, byweight of the third personal care composition, of hydrophobic benefitmaterial. The first personal care composition is capable of beingsubstantially dispensed prior to the second and third personal carecomposition. The second personal care composition is capable of beingsubstantially dispensed prior to the third personal care composition.

These and other features, aspects, and advantages of the presentinvention will become evident to those skilled in the art from a readingof the present disclosure with the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A and FIG. 1B illustrate a personal care article with three zoneshaving horizontal interfaces between the compositions in each zone.

FIG. 2A is a diagram of the distinguishable layers of a personal careproduct after centrifugation which can be measured in length tocalculate the concentration of hydrophobic benefit material in thepersonal care product using the Microcentrifugation Method describedbelow.

FIG. 2B and FIG. 2C are photographs that exemplify the measurement ofthe length of the benefit layer used to calculate the concentration ofthe hydrophobic benefit material within in centrifuged samples testedusing the Microcentrifugation Method described below.

FIG. 3 is a calibration curve calculated using a formula in theMicrocentrifugation Method described below.

FIG. 4 illustrates a graphic user interface analysis a personal careproduct phase distribution along the radial dimensions of the packageaccording to the MRI method described below.

FIG. 5 illustrates a graphic user interface analysis of a personal careproduct phase distribution along the height of the package according tothe MRI method described below.

FIG. 6A, FIG. 6B, and FIG. 6C are MRI images of hydrophobic benefitmaterial distribution profiles prior to and after simulated shippingconditions, as per the Dynamic Stability Shipping Method describedbelow.

FIG. 7A, FIG. 7B and FIG. 7C are MRI images of hydrophobic benefitmaterial distribution profiles of personal care products described inthe examples below.

FIG. 8 is a chart showing the benefit phase distribution profile of thehydrophobic benefit material in the personal care products described inthe examples below.

An appendix of figures is also provided, and includes:

FIG. 9 is a chart showing the lipid delivery profile according to anembodiment as described herein wherein the ratio of lathering agent tohydrophobic benefit agent varies across a treatment cycle from about70:30 through about 45:55 to about 80:20.

FIG. 10 is a graph showing the relative change in visual dryness usingwater and a embodiment of personal care composition having the lipiddelivery profile as shown in FIG. 9.

FIG. 11 is a graph showing the relative change in skin conditionmeasured with a corneometer using water and a embodiment of personalcare composition having the lipid delivery profile as shown in FIG. 9.

FIG. 12 is a graph showing the relative change in skin trans epidermalwater loss using water and a embodiment of personal care compositionhaving the lipid delivery profile as shown in FIG. 9.

FIG. 13 is a graph showing the relative change in visual dryness usingwater, a personal care composition having a lathering agent tohydrophobic benefit agent ratio of 44:45 and a embodiment of personalcare composition having the lipid delivery profile as shown in FIG. 9.

FIG. 14 is a graph showing the relative change in skin conditionmeasured with a corneometer using water, a personal care compositionhaving a lathering agent to hydrophobic benefit agent ratio of 44:45 anda embodiment of personal care composition having the lipid deliveryprofile as shown in FIG. 9.

FIG. 15 is a graph showing the relative change in skin trans epidermalwater loss using water, a personal care composition having a latheringagent to hydrophobic benefit agent ratio of 44:45 and a embodiment ofpersonal care composition having the lipid delivery profile as shown.

FIG. 16 is a graph showing the change in skin deformation over time.

FIG. 17 is a graph showing the relative change in Ue using water and aembodiment of personal care composition having the lipid deliveryprofile as shown in FIG. 9.

FIG. 18 is a graph showing the relative change in Ur using water and aembodiment of personal care composition having the lipid deliveryprofile as shown in FIG. 9.

FIG. 19 is a graph showing the relative change in Ue using water, apersonal care composition having a lathering agent to hydrophobicbenefit agent ratio of 44:45 and a embodiment of personal carecomposition having the lipid delivery profile as shown in FIG. 9.

FIG. 20 is a graph showing the relative change in Ur using water, apersonal care composition having a lathering agent to hydrophobicbenefit agent ratio of 44:45 and a embodiment of personal carecomposition having the lipid delivery profile as shown in FIG. 9.

FIG. 21 is a graph showing the relative change in total protein usingwater and a embodiment of personal care composition having the lipiddelivery profile as shown in FIG. 9

FIG. 22 is a graph showing the relative change in total protein usingwater, a personal care composition having a lathering agent tohydrophobic benefit agent ratio of 44:45 and a embodiment of personalcare composition having the lipid delivery profile as shown in FIG. 9

FIG. 23 is a graph showing the relative change in Keratin 1, 10 and 11normalized to soluble protein using water and a embodiment of personalcare composition having the lipid delivery profile as shown in FIG. 9

FIG. 24 is a graph showing the relative change Keratin 1, 10 and 11normalized to soluble protein using water, a personal care compositionhaving a lathering agent to hydrophobic benefit agent ratio of 44:45 anda embodiment of personal care composition having the lipid deliveryprofile as shown in FIG. 9.

FIG. 25 is a graph showing the lipid delivery profile according to anembodiment as described herein wherein the ratio of lathering agent tohydrophobic benefit agent varies across a treatment cycle from about70:30 through about 45:55 to about 80:20, wherein the volume ofdispensed composition is 250 ml.

FIG. 26 is a graph showing the lipid delivery profile according to anembodiment as described herein wherein the ratio of lathering agent tohydrophobic benefit agent varies across a treatment cycle from about70:30 through about 45:55 to about 80:20, wherein the volume ofdispensed composition is 450 ml.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

“Ambient conditions” as used herein, refers to surrounding conditions atone (1) atmosphere of pressure, 50% relative humidity, and 25° C.

“Biomarker” as used herein refers to any biological molecules (genes,proteins, lipids, metabolites) that, singularly or collectively, reflectthe current or predict future state of a biological system. Thus, asused herein, various biomarkers are indicators of the quality of skin interms of elasticity, dryness, condition, brightness, tone, smoothness,appearance of lines. Non-limiting examples of biomarkers include,elastic properties, visual properties of dryness and condition, thepresence of flaking, cohesiveness as evidenced by total protein, lipidcontent, trans epidermal water loss, cytokine expression, the presenceof one or more of keratins 1, 10 and 11. One or more modified biologicalparameters can be used to screen for materials that induce a positive ornegative effect on skin. The response of skin to treatment with personalcare compositions can also be assessed by measuring one or morebiomarkers.

“Comprising” as used herein means that other steps and other ingredientswhich do not affect the end result can be added. This term encompassesthe terms “consisting of” and “consisting essentially of.” Thecompositions and methods/processes of the present invention cancomprise, consist of, or consist essentially of the essential elementsand limitations of the invention described herein, as well as any of theadditional or optional ingredients, components, steps, or limitationsdescribed herein useful in personal cleansing compositions intended fortopical application to the hair or skin.

“Effective amount” as used herein means an amount of a compound orcomposition sufficient to significantly induce a positive skin benefit,including independently or in combination with other benefits disclosedherein. This means that the content and/or concentration of activecomponent in the formulation is sufficient that when the formulation isapplied with normal frequency and in a normal amount, the formulationcan result in the treatment of one or more undesired skin conditions(e.g., skin wrinkles). For instance, the amount can be an amountsufficient to inhibit or enhance some biochemical function occurringwithin the skin. This amount of active component may vary depending uponthe type of product, the type of skin condition to be addressed, and thelike.

“Headspace,” as used herein means the void volume that is locatedproximal to the dispensing orifice and the interface of the first zoneof the single chamber package. In the alternative, the headspace can becomprised within the first zone. The headspace of the personal carearticles of the present invention can be determined by the followingmethod or any other conventional method. First, an empty package isplaced on a balance and weighed. The total package volume is determinedby completely filling the package with deionized water and determiningthe deionized water weight and recording it as (V_(total)). The packageis then filled with a personal care composition leaving a headspace.Next, the package is placed on a balance and re-zero. The headspacevolume is filled with deionized water by a syringe. The weight ofdeionized water filled in the headspace is recorded as (V_(headspace)).The headspace is calculated as: V_(headspace)/V_(total)*100%.

“Hydrophobic benefit agent” as used herein, refers to hydrophobicbenefit materials that deliver skin conditioning, moisturization, andskin health benefits. Preferably, hydrophobic benefit agents areselected from the group consisting of petrolatum, lanolin, derivativesof lanolin (e.g. lanolin oil, isopropyl lanolate, acetylated lanolin,acetylated lanolin alcohols, lanolin alcohol linoleate, lanolin alcoholriconoleate) hydrocarbon oils (e.g. mineral oil) natural and syntheticwaxes (e.g. micro-crystalline waxes, paraffins, ozokerite, lanolin wax,lanolin alcohols, lanolin fatty acids, polyethylene, polybutene,polydecene, pentahydrosqualene) volatile or non-volatile organosiloxanesand their derivatives (e.g. dimethicones, cyclomethicones, alkylsiloxanes, polymethylsiloxanes, methylphenylpolysiloxanes), natural andsynthetic triglycerides (e.g. castor oil, soy bean oil, sunflower seedoil, maleated soy bean oil, safflower oil, cotton seed oil, corn oil,walnut oil, peanut oil, olive oil, cod liver oil, almond oil, avocadooil, palm oil, sesame oil) and combinations thereof.

“Liquid” as used herein means that the composition is generally flowableto some degree. “Liquids”, therefore, may include liquid, semi-liquid,cream, lotion or gel compositions intended for topical application toskin. The compositions may exhibit a viscosity of equal to or greaterthan about 1,500 (centipoise, hereinafter “cps”), equal to or greaterthan about 5,000 cps, equal to or greater than about 10,000 cps or equalto or greater than about 20,000 cps and no more than about 1,000,000cps, no more than about 500,000 cps, no more than about 300,000 cps, orno more than about 200,000 cps as measured by the T-Bar Viscosity Methoddescribed hereinafter.

“Lathering Agent” as used herein refers to a surfactant, which whencombined with water and mechanically agitated generates a foam or lathersufficient to cause a personal care composition to provide a lather.

“Package” includes any suitable container for personal care compositionsexhibiting a viscosity from about 1,500 centipoise (cP) to about1,000,000 cP, including but not limited to a bottle, tottle, tube, jar,non-aerosol pump and mixtures thereof.

“Personal care composition” as used herein, refers to compositionsintended for topical application to the skin or hair. The compositionsused in accordance with the present invention are rinse-offformulations, in which the product is applied topically to the skin orhair and then is subsequently rinsed within minutes from the skin orhair with water, or otherwise wiped off using a substrate withdeposition of a portion of the composition. The compositions also may beused as shaving aids. The personal care composition used in accordancewith the present invention is typically extrudable or dispensible from asingle chamber package. The personal care compositions used inaccordance with the present invention can be in the form of liquid,semi-liquid, cream, lotion or gel compositions intended for topicalapplication to skin. Examples of personal care compositions used inaccordance with the present invention can include but are not limited toshampoo, conditioning shampoo, hair conditioner, body wash, moisturizingbody wash, shower gels, skin cleansers, cleansing milks, hair and bodywash, in shower body moisturizer, pet shampoo, shaving preparations andcleansing compositions used in conjunction with or applied to adisposable cleansing cloth. The product forms contemplated for purposesof defining the compositions and methods of the present invention arerinse-off formulations by which it is meant that the product is appliedtopically to the skin or hair and then subsequently (i.e., withinminutes) rinsed away with water, or otherwise wiped off using asubstrate or other suitable removal means.

“Phase” as used herein refers to a distinguishable part in a cycle oftreatment or application of a personal care product according to theinvention. For purposes hereof, a phase need not be limited to aparticular period of time. Phases are distinct from one another in thatthe properties, most particularly the ratios of lathering agent tohydrophobic benefit agent, of a personal care composition vary betweensequential phases. Thus, in a cycle comprising three phases of treatmentor application, each phase may involve use of personal care compositionsthat vary relative to one another, for example wherein the ratios oflathering agent to hydrophobic benefit agent vary between each of thephases. In another example, in a cycle comprising three phases oftreatment or application, two of the phases may involve use of personalcare compositions that do not vary relative to one another while a thirdphase varies from the other two. In yet another example in a cyclecomprising two phases of treatment or application, each phase mayinvolve use of personal care compositions that vary relative to oneanother, for example wherein the ratios of lathering agent tohydrophobic benefit agent vary between each of the phases. The terms“Premium Experience Phase” refers to phases in which the components in apersonal care composition are associated with delivery of one or moreexperiential benefits to the user at the time of use, such as latheringand delivery of scent for excellent in-use characteristics duringcleansing process. The term “Conditioning Phase” refers to phases inwhich the components in a personal care composition are associated withdelivery of one or more benefits during use, for example, deposition ofhydrophobic benefit agent on the skin, that provide long term benefitsafter use.

“Sagging” as used herein means the laxity, slackness, or the likecondition of skin that occurs as a result of loss of, damage to,alterations to, and/or abnormalities in dermal elastin, muscle and/orsubcutaneous fat.

“Signs of aging” include, but are not limited to, all outward visiblyand tactilely perceptible manifestations as well as any other macro ormicro effects due to skin aging. Such signs may be induced or caused byintrinsic factors or extrinsic factors, e.g., chronological aging and/orenvironmental damage. These signs may result from processes whichinclude, but are not limited to, the development of texturaldiscontinuities such as wrinkles and coarse deep wrinkles, fine lines,skin lines, crevices, bumps, large pores (e.g., associated with adnexalstructures such as sweat gland ducts, sebaceous glands, or hairfollicles), or unevenness or roughness, loss of skin elasticity (lossand/or inactivation of functional skin elastin), sagging (includingpuffiness in the eye area and jowls), loss of skin firmness, loss ofskin tightness, loss of skin recoil from deformation, discoloration(including undereye circles), blotching, sallowness, hyperpigmented skinregions such as age spots and freckles, keratoses, abnormaldifferentiation, hyperkeratinization, elastosis, collagen breakdown, andother histological changes in the stratum corneum, dermis, epidermis,the skin vascular system (e.g., telangiectasia or spider vessels), andunderlying tissues (e.g., fat and/or muscle), especially those proximateto the skin.

“Skin,” as used herein, refers to keratin-containing layers disposed asthe outermost protective covering of mammals (e.g., humans, dogs, cats,etc.) which includes, but is not limited to, skin, mucosa, lips, hair,toenails, fingernails, cuticles, hooves, etc.

“Smoothing” and “softening” as used herein mean altering the surface ofthe skin such that its tactile feel is improved.

“Surfactant component” as used herein means the total of all anionic,nonionic, amphoteric, zwitterionic and cationic surfactants in a phase.When calculations are based on the surfactant component, water andelectrolyte are excluded from the calculations involving the surfactantcomponent, since surfactants as manufactured typically are diluted andneutralized.

“Statically stable” as used herein, unless otherwise specified, refersto a personal care article that comprise at least two compositions thatmaintain at least two “separate” zones with at least two separatebenefit concentrations zones contained within a single chamber packageat ambient conditions for a period of at least about 180 days.Alternatively, static stability can be determined by acceleratedprotocol at elevated temperature. One accelerated protocol is based onpassing static stability after 10 days at 50° C. By “separate” is meantthat there is substantially no mixing of compositions contained in thezones, detected by the benefit analysis method, described hereinafter,prior to dispensing of the composition.

“Structured,” as used herein means having a rheology that confersstability on the personal care composition. The degree of structure isdetermined by characteristics determined by one or more of the followingmethods the Yield Stress Method, or the Zero Shear Viscosity Method orby the Ultracentrifugation Method, all in the Test Methods below.Accordingly, a surfactant phase of the composition used in accordancewith the present invention is considered “structured,” if the surfactantphase has one or more of the following properties described belowaccording to the Yield Stress Method, or the Zero Shear Viscosity Methodor by the Ultracentrifugation Method. A surfactant phase is consideredto be structured, if the phase has one or more of the followingcharacteristics:

A. a Yield Stress of greater than about 0.1 Pascal (Pa), more typicallygreater than about 0.5 Pa, even more typically greater than about 1.0Pa, still more typically greater than about 2.0 Pa, still even moretypically greater than about 3 Pa, and even still even more typicallygreater than about 5 Pa as measured by the Yield Stress and Zero ShearViscosity Method described hereafter:

B. a Zero Shear Viscosity of at least about 500 Pascal-seconds (Pa-s),typically at least about 1,000 Pa-s, more typically at least about 1,500Pa-s, even more typically at least about 2,000 Pa-s; or

C. a Structured Domain Volume Ratio as measured by theUltracentrifugation Method described hereafter, of greater than about40%, typically at least about 45%, more typically at least about 50%,more typically at least about 55%, more typically at least about 60%,more typically at least about 65%, more typically at least about 70%,more typically at least about 75%, more typically at least about 80%,even more typically at least about 85%.

“Topical application”, “topically”, and “topical”, as used herein, meanto apply (e.g., spread, spray) the compositions used in accordance withthe present invention onto the surface of the skin.

“Tottle” as used herein refers to a bottle which rests on the neck ormouth which its contents are filled in and dispensed from, but it isalso the end upon which the bottle is intended to rest or sit upon forstorage by the consumer and/or for display on the store shelf, asdescribed in the commonly owned U.S. patent application Ser. No.11/067,443 filed on Feb. 25, 2005 to McCall et al, entitled “Multi-phasePersonal Care Compositions, Process for Making and Providing, andArticle of Commerce.”

“Treating” or “treatment” or “treat” as used herein includes regulatingand/or immediately improving skin cosmetic appearance and/or feel. Asused herein, “regulating” or “regulation” means maintaining or improvingthe health and/or cosmetic appearance, and includes bothprophylactically regulating and/or therapeutically regulating.Regulation of skin condition, namely mammalian and in particular humanskin, hair, or nail condition, is often required due to conditions whichmay be induced or caused by factors internal and/or external to thebody. Examples include environmental damage, radiation exposure(including ultraviolet radiation), chronological aging, menopausalstatus (e.g., post-menopausal changes in skin, hair, or nails), stress,diseases, disorders, etc. For instance, “regulating skin, hair, or nailcondition” includes prophylactically regulating and/or therapeuticallyregulating skin, hair, or nail condition, and may involve one or more ofthe following benefits: thickening of skin, hair, or nails (e.g.,building the epidermis and/or dermis and/or sub-dermal [e.g.,subcutaneous fat or muscle] layers of the skin, and where applicable thekeratinous layers of the nail and hair shaft) to reduce skin, hair, ornail atrophy, increasing the convolution of the dermal-epidermal border(also known as the rete ridges), preventing loss of skin or hairelasticity (loss, damage and/or inactivation of functional skin elastin)such as elastosis, sagging, loss of skin or hair recoil fromdeformation; melanin or non-melanin change in coloration to the skin,hair, or nails such as under eye circles, blotching (e.g., uneven redcoloration due to, e.g., rosacea) (hereinafter referred to as “redblotchiness”), sallowness (pale color), discoloration caused bytelangiectasia or spider vessels, and graying hair.

“Zone” as used herein refers to a domain or region within a singlechamber package which corresponds to a composition of the personal carearticle. The interface between the zones can be distinct or gradual orseparated by another zone. The amount contained within a zone can bedefined by a percentage of the package volume and a zone comprises atleast 10% of the package volume of a given package, excluding the volumeof the package corresponding to the necessary headspace or void volumeand the closure, as shown in FIG. 1A and FIG. 1B of the presentinvention. In one aspect, the first personal care composition, thesecond personal care composition and third personal care compositionswithin a the first zone, second zone or third zone is homogeneous. Inthis case, the concentration of hydrophobic benefit material is constantwithin the zone. In another aspect, the personal care composition withinthe first, second or third zone is inhomogeneous, such that theconcentration of hydrophobic benefit material varies within the zone.The level of hydrophobic benefit material can show an increasing ordecreasing trend.

All percentages, parts and ratios are based upon the total weight of thecompositions used in accordance with the present invention, unlessotherwise specified. All such weights as they pertain to listedingredients are based on the active level and, therefore; do not includesolvents or by-products that may be included in commercially availablematerials, unless otherwise specified. The term “weight percent” may bedenoted as “wt. %” herein. Except where specific examples of actualmeasured values are presented, numerical values referred to hereinshould be considered to be qualified by the word “about.”

All molecular weights as used herein are weight average molecularweights expressed as grams/mole, unless otherwise specified.

II. Methods and Regimens for Treating Skin

The personal care compositions used in accordance with the presentinvention are used in a conventional manner for cleansing andconditioning skin. The personal care compositions used in accordancewith the present invention are typically applied topically to thedesired area of the skin in an amount sufficient to provide effectivedelivery of the skin cleansing agent, hydrophobic material, and in someembodiments particles and other agents and actives to the appliedsurface. The compositions can be applied directly to the skin orindirectly via the use of a cleansing puff, washcloth, sponge or otherimplement. The compositions are typically diluted with water prior to,during, or after topical application, and then subsequently the skin isrinsed or wiped off, typically rinsed off of the applied surface usingwater or a water-insoluble substrate in combination with water.

The present invention is therefore also directed to methods of cleansingthe skin through the above-described application of the compositions ofthe present invention. An effective amount of the composition forcleansing and conditioning the skin is applied to the skin, that in someexamples has been wetted with water, and then rinsed off. Such effectiveamounts generally range from about 1 gm to about 50 gm, and from about 1gm to about 20 gm.

In general, a typical method for cleansing and conditioning the skincomprises the steps of: a) wetting the skin with water, b) applying aneffective amount of the personal care composition to the skin, and c)rinsing the applied areas of skin with water. These steps can berepeated as many times as desired to achieve the desired cleansing andconditioning benefit.

Treatment Regimens

In various embodiments, the invention provides methods and regimens foruse of a personal care composition having varied ratios of latheringagent to hydrophobic benefit agent. The composition is used over aperiod of time, alternately referred to as a treatment time, thatincludes two or more phases. In some embodiments, the treatment periodincludes three phases, starting with first phase in which a highlathering agent (surfactant) is used that provides a premium userexperience through high lather and fragrance delivery. According to suchembodiments, as use progresses into a second phase, a high lipid“plateau” provides conditioning through high hydrophobic benefit agentcontent, and in a final phase a high lathering agent (surfactant) isused that provides a premium user experience through high lather andfragrance delivery. In other embodiment, the order of the phases may beswitched and a treatment period may comprise only two phases, or it maycomprise more than three phases.

In various embodiments, skin treatment regimens are provided comprising(i) providing to a user a composition formulated to comprise varyingratios of lathering agent to hydrophobic benefit agent, said varyingratios being either continuous or discrete; and (ii) applying theprovided composition to the skin of the user in a treatment cyclecomprising at least first and second phases. The composition appliedduring the first phase comprises a first of the varying ratios, and thecomposition applied during the second phase comprises a second of thevarying ratios. In some embodiments, said second ratio is lower than thefirst ratio. In some embodiments, the treatment cycle comprises a thirdphase, and the composition applied therein comprises a third of thevarying ratios. In accordance with the invention, provided are regimensfor the delivery of a rinse-off personal skin care composition. Someembodiments include the steps of dispensing from a personal care articlea personal care composition that comprises a lathering agent and ahydrophobic benefit agent, wherein the article operates to dispense thecomposition in aliquots, and wherein the ratio of lathering agent tohydrophobic benefit agent varies in successively dispensed aliquots ofthe composition over the course of dispensing the article contents suchthat the amount of hydrophobic benefit agent in two or more successivealiquots is different. According to such embodiments, the steps includeapplying a first aliquot of the personal care composition to a user'sskin together with water, wherein the lathering agent provides latherwhen contacted on the user's skin with water and rinsing the personalcare composition from the user's skin, wherein a portion of thehydrophobic benefit agent is deposited and remains on the user's skinafter rinsing.

In accordance with some embodiments of the regimens, the steps include:application of a composition to skin of a user in phases over atreatment cycle. It will be understood that a treatment cycle isdescribed herein as been achieved in phases, however, the term phrasesis intended to be non-limiting with respect to time or sequence of thesteps of a treatment cycle. In the various embodiments, the compositioncomprises varying ratios of a lathering agent to a hydrophobic benefitagent. A treatment cycle includes a first phase characterized by theapplication of the composition having a first ratio of the varyingratios, an intermediate phase characterized by the application of thecomposition having a second ratio of the varying ratios that is lowerthan the first ratio, and a final phase characterized by the applicationof the composition having a third ratio of the varying ratios that ishigher than the intermediate phase.

The invention also provides regimens for sustaining consumer use of atreatment for skin. In various embodiments, the regimen involvesapplication of the composition to a user's skin in a treatment cyclehaving a first phase wherein the ratio of lathering agent to hydrophobicbenefit agent is high and provides a relatively appealing sensation tothe consumer, an intermediate phase wherein the ratio of lathering agentto hydrophobic benefit agent is low and provides a relatively lessappealing sensation to the consumer, and a final phase wherein the ratioof lathering agent to hydrophobic benefit agent is high and provides arelatively appealing sensation to the consumer.

The invention also provides regimens for maintaining the quality of skinwith a rinse-off personal care composition which include the steps ofapplying the composition to a user's skin on a daily basis for a periodof days, wherein the composition is a rinse-off personal skin carecomposition comprising a hydrophobic benefit agent and a latheringagent, and wherein the ratio of lathering agent to hydrophobic benefitagent varies over the period of application, the period of days ofapplication comprising, in any order, a premium experience phase whereinthe ratio of lathering agent to hydrophobic benefit agent is high, thepremium experience phase characterized by maximal delivery of lather andscent, and a conditioning phase wherein the ratio of lathering agent tohydrophobic benefit agent is low, the conditioning phase characterizedby maximal hydrophobic benefit agent deposition. In some embodiments thesequence of the phases is the premium experience phase followed by theconditioning phase. In other embodiments, the sequence of the phases isthe conditioning phase followed by the premium experience phase. In yetother embodiments, the sequence of the phases is a premium experiencephase, followed by a conditioning phase, followed by a premiumexperience phase.

In some embodiments, said third ratio higher than the second ratio. Insome embodiments, the composition is provided to the user through adelivery article adapted to dispense the composition in discretealiquots of approximately equal volume. In some embodiments, thecomposition comprises a continuum of varying ratios, and at least everyother aliquot provided to the user has a different ratio of latheringagent to hydrophobic benefit agent. In some embodiments, every aliquotprovided to the user has a different ratio. In some embodiments, atleast every other aliquot provided and applied during the first phasehas a lower ratio of lathering agent to hydrophobic benefit agent.

In accordance with some embodiments, the composition is provided in adelivery article that contains sufficient composition for at least onetreatment cycle. According to such embodiments, the delivery article isadapted to dispense the composition in discrete aliquots ofapproximately equal volume, and wherein aliquots of the composition areapplied until the contents of the delivery article are substantiallydepleted. In some embodiments the each aliquot has the same approximatevolume. In some embodiments the volume of each successively dispensedaliquot increases. In some embodiments a first dispensed aliquotcomprises a first ratio of the varying ratios, and a subsequentdispensed aliquot comprises a second ratio of the varying ratios that isdifferent from the ratio of the first aliquot. According to suchembodiments, an aliquot dispensed subsequent to the second aliquotcomprises a third ratio of the varying ratios that is different from theratio of the second aliquot. In some embodiments, an aliquot dispensedsubsequent to the second aliquot comprises a third ratio of the varyingratios that is different from the ratio of the first aliquot. In someembodiments an aliquot dispensed subsequent to the second aliquotcomprises a third ratio of the varying ratios that is different from theratios of the first and the second aliquots.

Suitable aliquots for application during the first phase include, butare not limited to, those having a ratio of lathering agent tohydrophobic benefit agent from about 90:10 to about 50:50. Accordingly,non-limiting examples of suitable aliquots for application during thefirst phase are those having ratios of 90:10, 85:15, 80:20, 75:25,70:30, 65:35, 60:40, 55:45, and 50:50. In some embodiments, at leastevery other aliquot provided and applied during the second phase has alower ratio of lathering agent to hydrophobic benefit agent. Suitablealiquots for application during the second phase include, but are notlimited to, those having a ratio of lathering agent to hydrophobicbenefit agent from about 50:50 to about 10:90.

Accordingly, non-limiting examples of suitable aliquots for applicationduring the second phase are those having ratios of 50:50, 45:55, 40:60,35:65, 30:70, 25:75, 20:80, 15:85, and 10:90. In some embodiments, atleast every other aliquot applied during the third phase has a higherratio of lathering agent to hydrophobic benefit agent. Suitable aliquotsfor application during the third phase include, but are not limited to,those having a ratio of lathering agent to hydrophobic benefit agentfrom about 50:50 to about 90:10. Accordingly, non-limiting examples ofsuitable aliquots for application during the third phase are thosehaving ratios of 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15,and 90:10.

In some embodiments, the composition comprises discrete varying ratios,and each aliquot provided to the user during a phase has the same ratioof lathering agent to hydrophobic benefit agent. For example, thecomposition may be in discrete zones within the delivery article, eachzone having a different ratio of lathering agent to hydrophobic benefitagent. As further example, each zone may correspond to a phase of thetreatment regimen. In the embodiments wherein the composition comprisesdiscrete ratios of lathering agent to hydrophobic benefit agent,suitable aliquots for application during the first phase include, butare not limited to, those having a ratio from about 90:10 to about50:50. Accordingly, non-limiting examples of suitable aliquots forapplication during the first phase are those having ratios of 90:10,85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, and 50:50.

In the embodiments wherein the composition comprises discrete ratios oflathering agent to hydrophobic benefit agent, suitable aliquots forapplication during the second phase include, but are not limited to,those having a ratio from about 50:50 to about 10:90. Accordingly,non-limiting examples of suitable aliquots for application during thesecond phase are those having ratios of 50:50, 45:55, 40:60, 35:65,30:70, 25:75, 20:80, 15:85, and 10:90. In the embodiments wherein thecomposition comprises discrete ratios of lathering agent to hydrophobicbenefit agent, suitable aliquots for application during the third phaseinclude, but are not limited to, those having a ratio from about 50:50to about 90:10. Accordingly, non-limiting examples of suitable aliquotsfor application during the third phase are those having ratios of 50:50,55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, and 90:10.

In accordance with some embodiments, the composition is applied on adaily basis. It will be appreciated that treatment times and frequencymay vary based upon the user, and as such, treatment may be on a lessthan daily basis, or may be more often. In other embodiments, thetreatments may be less frequent, for example weekly or monthly, or insome other interval of time.

In accordance with the methods, the composition is provided in adelivery article that is adapted for use in accordance with apredetermined time of treatment or a predetermined approximate number ofinstances of treatment, or both. Thus, in some embodiments, the deliveryarticle is adapted to deliver sufficient composition for one or two ormore treatment cycles. In some embodiments, the delivery article isadapted to deliver the composition for each treatment cycle in anapproximate number of aliquots or units. In such embodiments, thealiquots may be the same in volume or may vary. In some embodiments thenumber of aliquots or units to be dispensed per phase or in an articleis a predetermined number that defines the approximate number ofinstances of use, either in days, weeks or months.

In some embodiments the composition is applied through a treatment cyclein a time interval of about thirty days. For example, the first phase ofthe treatment cycle may be from about 3 to 7 days, the intermediatephase of the treatment cycle may be from about 6 to 14 days, and thefinal phase of the treatment cycle may be from about 6 to 14 days. Inanother example, the first phase of the treatment cycle may be fromabout 2 to 5 days, the intermediate phase of the treatment cycle may befrom about 3 to 7 days, and the final phase of the treatment cycle maybe from about 14 to 21 days.

In another embodiment, the composition is applied through a treatmentcycle in a time interval of about fifty days. In one example, the firstphase of the treatment cycle may be from about 3 to 7 days, theintermediate phase of the treatment cycle may be from about 10 to 28days, and the final phase of the treatment cycle may be from about 14 to20 days.

In another embodiment, the applied through a treatment cycle in a timeinterval of about fifty-six days. In one example, the first phase of thetreatment cycle may be from about 2 to 7 days, the intermediate phase ofthe treatment cycle may be from about 3 to 28 days, and the final phaseof the treatment cycle may be from about 6 to 21 days

In accordance with various embodiments, the ratios of lathering agent tohydrophobic benefit agent may vary in each phase across a broad possiblerange. In some embodiments, the ratio of lathering agent to hydrophobicbenefit agent is at a maximum of about 75:25 during the first phase, andthe ratio of lathering agent to hydrophobic benefit agent is at aminimum of about 45:55 during the intermediate phase, and the ratio oflathering agent to hydrophobic benefit agent is at a maximum of about75:25 during the final phase. In other embodiments, the ratio oflathering agent to hydrophobic benefit agent is at a maximum of about70:30 during the first phase, and the ratio of lathering agent tohydrophobic benefit agent is at a minimum of about 45:55 during theintermediate phase, and the ratio of lathering agent to hydrophobicbenefit agent is at a maximum of about 80:20 during the final phase. Inyet other embodiments, the ratio of lathering agent to hydrophobicbenefit agent is at a maximum of about 75:25 during the first phase, andthe ratio of lathering agent to hydrophobic benefit agent is at aminimum of about 45:55 during the intermediate phase, and the ratio oflathering agent to hydrophobic benefit agent is at a maximum of about75:25 during the final phase. In some general embodiments, the ratio oflathering agent to hydrophobic benefit agent is at a maximum in therange from about 50:50 to 90:10 during the first phase, and the ratio oflathering agent to hydrophobic benefit agent is at a minimum in therange from about 10:90 to 50:50 during the intermediate phase, and theratio of lathering agent to hydrophobic benefit agent is at a maximum inthe range from about 50:50 to 90:10 during the final phase.

It will be appreciated that the variations in ratios in each phase andbetween the phases may vary independently of the interval time oftreatment, and that the number of days of treatment during any phase ina described interval may vary. Further, it will be appreciated that thenumber of aliquots or units of composition dispensed or used in atreatment cycle, during any phase, or in any single application mayvary, and that the volume of aliquots may vary.

In accordance with some embodiments, a delivery article is adapted todeliver composition formulated to match a population profile, whereinthe profile reflects preferences in a population for compositionproperties selected from maximum hydrophobic benefit agent content,lathering, scent, color, opalescence, thickness, and combinations ofthese. Methods of identifying population profiles and developingpersonal care compositions are described herein.

In accordance with various embodiments, the composition formulation usedin accordance with the methods may include one or more additionalbenefit agents. Non limiting examples of benefit agents includesvitamins, vitamin derivatives, sunscreens, desquamation actives,anti-wrinkle actives, anti-atrophy actives, anti-oxidants, skin soothingagents, skin healing agents, skin lightening agents, skin tanningagents, anti-acne medicaments, essential oils, sensates, pigments,colorants, pearlescent agents, interference pigments, particles,hydrophobically modified non-platelet particles and combinationsthereof. Other benefit agents and materials as described herein withrespect to representative composition embodiments may also be used.Likewise, other formulation components, including lathering/surfactantagents and hydrophobic benefit agents may be selected as describedherein. Additional benefit agents may be provide with either or both thelathering agent and the hydrophobic benefit agent. Examples of somespecific benefit agents include exfoliating agents, niacinamide, vitaminE (tocopherol or tocotrieneol), collagen.

According to the various embodiments, personal care compositions providea lathering agent that produces a lather that varies with the variedratios of lathering agent and hydrophobic benefit agent. In someembodiments the lather volume of the composition is greater than fromabout 800 ml to 1500 ml by the cylinder lather method. It will thus beappreciated by those in the art that in accordance with the cylindermethod, the lather volume provided by a personal care composition may befrom about 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300,1350, 1400, 1450, and 1500 or more ml. Of course it will be appreciatedthat in some embodiments, particular with respect to embodiments andphases wherein the ratio of lathering agent to hydrophobic benefit agentis low, that the lather volume will be lower or substantially lower thanthe above stated range, and that in some embodiments the lather volumemay be from 1500 to 1750 to 1900, to 2000 or more ml. It will also beappreciated that other methods described or otherwise known in the artmay be used to characterize lather and lather volume and that thedescription herein is not limiting, such that the lather properties ofthe compositions used as described herein may be described in otherterms.

In accordance with varying embodiments, the methods and regimens involvethe use of personal care compositions provided in one or more deliveryarticles. In some embodiments the ratios of the lathering agent tohydrophobic benefit agent in the composition vary as a function ofcontainment location in the single delivery article. In some embodimentsthe composition is contained within discrete zones of the deliveryarticle and wherein ratios of lathering agent to hydrophobic benefitagent are different in each zone. According to such embodiments, thediscrete zones are physically separated chambers defined in the deliveryarticle. In some embodiments the personal care composition is providedin a delivery article adapted to dispense the composition in discretealiquots of approximately equal volume. In some such embodiments, thedelivery article contains sufficient composition for a predeterminedapplication period. In some embodiments aliquots of the composition aredispensed and applied until the contents of the delivery article aresubstantially depleted

In some embodiments the ratios of the lathering agent to hydrophobicbenefit agent in the composition vary continuously from the first phasethrough the final phase. It will be appreciated that the variationacross a phase or phases may be influenced by the volume increments ofcomposition provided. In some embodiments, two or more sequentialincrements of provided composition may be the same with respect to theratios of lathering agent to hydrophobic benefit agent. In otherembodiments, each increment may be the same.

According to some embodiments, the quality of the users skin after theconditioning phase exhibits improvement sufficient to be detected bymeasurement of one or more of reduction of visual dryness, reduction intrans-epidermal water loss, increased skin hydration, increased elasticextension, increased elastic recovery, increased firmness, reduction intotal protein, increase in the amount of one or more of Keratin 1,Keratin 10 and Keratin 11, and decrease in cytokine expression.According to some embodiments the quality of the users skin ismaintained through the premium experience and conditioning phases asevidenced by no measurable variation in the properties of visualdryness, trans-epidermal water loss, skin hydration, elastic extension,elastic recovery, firmness, total protein, the amount of one or more ofKeratin 1, Keratin 10 and Keratin 11, and cytokine expression ascompared with normal healthy control skin. It will be appreciated thatthe indicators of skin quality are not limited to those identifiedherein above and that other identifiers or indicators known in the artmay also be assessed to determine improvement of skin quality accordingto the methods hereof.

Use of Biomarkers

One or more potential formulations of personal care compositions mayscreened against one or more biomarkers to assess efficacy of thecomposition with respect to skin improving benefit. Graphical data shownin the appendix of figures herein provides evidence regarding theresults using the methods and compositions described herein.

Also provided are methods for improving the quality of skin that areevidenced by measurable improvement in one or more biomarker indicators.According to such methods, in some embodiments the steps includedispensing from a personal care article a personal care composition thatcomprises a hydrophobic benefit agent, applying the personal carecomposition to a user's skin together with water, rinsing the personalcare composition from the user's skin, wherein a portion of thehydrophobic benefit agent is deposited and remains on the user's skinafter rinsing. According to such embodiments, the steps further includerepeating the steps of applying and rinsing on at least a once dailybasis over a time interval of successive days, the time interval of usesufficient to permit detection of measurable improvement in at least oneskin property selected from (i) reduction of visual dryness, a reductionin trans-epidermal water loss, increased skin hydration, increasedelastic extension, increased elastic recovery, increased firmness and(ii) reduction in total protein, an increase in the amount of one ormore of Keratin 1, Keratin 10 and Keratin 11, and a decrease in cytokineexpression. In some such embodiments, the composition comprises alathering agent and wherein the article operates to dispense thecomposition in aliquots, and wherein the ratio of lathering agent tohydrophobic benefit agent varies in successively dispensed aliquots ofthe composition over the course of dispensing the article contents suchthat the amount of hydrophobic benefit agent in two or more successivealiquots is different.

According to the various embodiments, evidence of improvement usingbiomarkers is determined using methods known in the art. For example,one or more such measurable improvement can include a reduction ofvisual dryness, a reduction in trans-epidermal water loss, increasedskin hydration, wherein visual dryness is measured using corneometer andother known devices and techniques. In another example a measurableimprovement is one or more of increased elastic extension, increasedelastic recovery, increased firmness, measured using a cutometer andother known devices and techniques. In another example a measurableimprovement is one or more of reduction in total protein, increase inthe amount of one or more of Keratin 1, Keratin 10 and Keratin 11,decrease in one or more inflammatory cytokine expression, as measuredfrom tissue or cell samples that may be obtained using known techniquessuch as skin strip methods described herein, biopsy, or other method ofsampling. Measurements of total protein, specific proteins may be madeusing conventional techniques, and may include one or more affinityagents and assays as described herein and otherwise known in the art.

Also provided are methods for identifying a formulation comprising ahydrophobic benefit agent useful for improving the skin (stratum corneumbarrier) in a human subject. Embodiments of such methods includegenerating one or more negative skin profiles for a human subject havingdry or damaged skin; contacting the skin of the human subject with aproposed rinse-off personal care formulation by generating one or moretest profiles and comparing the one or more test profiles to the one ormore negative profiles and identifying the proposed formulation aseffective if the test profile is directionally shifted away from thenegative reference profile and shows at least one skin property selectedfrom (i) reduction of visual dryness, a reduction in trans-epidermalwater loss, increased skin hydration, increased elastic extension,increased elastic recovery, increased firmness and (ii) reduction intotal protein, an increase in the amount of one or more of Keratin 1,Keratin 10 and Keratin 11, and a decrease in cytokine expression.

In one embodiment, the screening step comprises: (1) placing potentialformulations of personal care composition in contact with skin or skincells that exhibit need for improvement in terms of exhibiting any oneor more signs of dryness or aging, the contact for a period of timesufficient to enable action on the skin tissue or cell. Typically, thetime of action will be commensurate with the typical time of applicationof a rinse-off product as used conventionally; (2) repeating thetreatment in parallel with control cells or tissue; (3) repeating thetreatment in parallel with one or more control compositions, including,for example, water; (4) isloating samples from the skin or cells foranalysis; (5) performing proteomic analysis and/or transcriptomicanalysis and/or genomic analysis, partial or complete, for assessing theeffect of the test composition; and (6) comparing the results with thecontrols.

Optimizing Compositions and Methods for Populations

It will be appreciated that the methods hereof are useful for benefitingusers from a variety of populations. Accordingly, also provided aremethods for developing personal care compositions and regimens oftreatment for members of various populations. The methods involveunderstanding the preferences of the target populations. For example,North American consumers are accustomed to thicker personal carecompositions and heavier skin feel than consumers in China. Accordingly,when designing a premium anti-aging body wash and methods of use, thepersonal care compositions must comply with regional expectationsbalanced with delivery of the consumer desired skin benefits. Thus, forexample, for one target population, the personal care composition lipidprofile varies from 25% to 55%, giving consumers not only improvedpersonal care composition aesthetics and in-use experience, but optimalperformance in terms of conditioning. For another target population,personal care composition lipid profile varies from 10-15% lipid.Similar preferences exist with respect to personal care compositiontexture, consistency, lather character and primary benefit focus. Forexample, while some eastern consumers expect personal care compositionsthat are of thinner consistency and lighter skin feel, other consumersare more similar to American consumers—expecting more from theirpersonal care compositions, enjoying thicker consistencies and are moreopen to heavier skin feels. Thus, methods are provided for providing arange of personal care compositions (a global menu) for the consumers invarious populations, such as populations that are definedgeographically.

The various embodiments include identifying a target population anddeveloping a population profile with respect to a rinse-off personalcare composition used for cleansing and moisturizing comprising thesteps of determining the population preferences for maximum amount ofhydrophobic benefit agent, and determining the population preferencesfor lather volume, lather texture, and lathering speed, compositionthickness, color, translucence, opalescence, and scent. Such embodimentsfurther include the steps of formulating a personal care compositionreflecting a population profile, wherein the composition comprisesvarying ratios of a lathering agent to a hydrophobic benefit agent,configuring a delivery article adapted to dispense the composition indiscrete aliquots of approximately equal volume, and adapted to containthe composition so as to dispense the composition in phases comprisingat least a first phase comprising a first ratio of the varying ratios oflathering agent to hydrophobic benefit agent, and a second phasecomprising a second ratio of the varying ratios of lathering agent tohydrophobic benefit agent that is different than the first ratio. Insome such embodiments, the steps further include manufacturing thecomposition for the target population; and providing the composition inthe delivery article. It will be appreciated that the method may berepeated for a different target population.

III. Treatment Examples Example 1 Personal Care Composition Features andBenefits

Factors Benefits 1. Skin Enhancement Minimizing lines Improving skintone Helping skin look younger 2. Rinsing/Clean Feel Not leaving skingreasy or coated Rinsing easily from skin Leaving skin feeling clean 3.Moisturization Not leaving skin dry/cracked Leaving skin soft/smoothHydrating and locking in Moisture 4. Scent Having a pleasant scentduring use Having a pleasant scent in bottle Leave long lasting scent onskin 5. Lather Providing right lather amount Lathering quickly andeasily Providing rich, creamy lather

Example 2 Clinical Study: Evaluation of Skin Indicator Response

A study was undertaken to evaluate the response of a variety of skinindicators using an array of different personal care compositions andwater. The study was 29 days in duration, with a 7 day interval ofpreconditioning, 21 days of treatment and 1 regression day. Skin wasanalyzed at various points from the beginning through the end of thestudy period. The objective of the study was to characterize the dryskin improvement profile of several body wash prototypes and to generatesamples to assess treatment's effects on stratum corneum indicators(also referred to as biomarkers).

Leg wash studies are used to evaluate the beneficial effects of personalcare products on dry leg skin. Leg wash studies are designed toapproximate consumer-relevant exposure levels, e.g. washing frequency.The technique used in this study is a modification of a publishedprocedure (Ertel, et al, 1999).

The study was conducted over 29 consecutive days, including a 7-daypreconditioning phase, a 21-day treatment phase and 1 day of regression.This randomized study employed an incomplete block design in which 4 ofthe 5 treatments was evaluated on each subject, 2 treatments on eachleg.

After the 7-day preconditioning phase, subjects returned to the testfacility to have the skin on their lower legs evaluated by an expertgrader. Only subjects which exhibited sufficient dryness on all of thetreatment sites qualified to continue into the treatment phase.

Technicians treated each qualified subjects' lower legs in a controlledmanner with the assigned treatments once daily for 21 days. Subjects'legs were visually evaluated for dryness and redness at several pre andpost-treatment times as outlined in the following study schedule.Non-invasive instrumental measurements of stratum corneum hydration(Corneometer 825), barrier function (Dermalab TEWL (trans epidermalwater loss)), and viscoelasticity (Cutometer) were made on the treatmentsites following visual evaluations.

Preconditioning Phase Procedure

Prospective subjects were selected on the basis of their ability to meetthe inclusion and exclusion criteria on DCF 1 and must have providedwritten informed consent. During preconditioning, enrolled subjects useda bar of Olay® with no exfoliating beads provided by the test facilityin place of their usual product(s) for bathing and showering. Theycontinued to use this product throughout their participation. Subjectsalso received a set of instructions to be followed during the study.

Treatment Phase Procedure

Before initial grading on Study Day 8, test facility personnel markedoff the leg application areas [two 70 cm² areas (7 cm across×10 cmdown)] on the outer aspect of the subjects' lower legs using a templateand laboratory marking pen (corner brackets are sufficient to delineateeach area). Trained clinical assistants treated each subject's legsaccording to the procedure outlined in the Treatment Procedure. Ingeneral, the following should be noted:

The “No Treatment” site (code A) was wetted initially, rinsed, and driedper the normal wash procedure. During the “product application” portionof the procedure, the site was timed for the 90 sec. “residence” but didnot have product or additional water applied, nor underwent any of thephysical manipulation (i.e., rubbing with fingers or implement).

Clinical Assistants wore disposable gloves during wash procedure,changed them between treatments and between subjects.

Clinical Assistants verified the correct treatment sequence anddocumented such before treating each subject.

The procedure was conducted once each day for 21 consecutive days.

The body wash products were applied using puffs. Puffs were pre-labeledwith subject number and treatment code, and used accordingly throughoutthe treatment phase.

The puff treatment procedure for all puffs was conducted daily after allproduct treatments were completed on each subject (except on the finalday of treatment.).

Product/Puff Preparation and Placement

The Sponsor provided puffs for use in application of body washes. All ofthe puffs were treated with 9.3 ml of the appropriate treatment codeeach day after treatment (except on the final day of treatment.)according to the procedure outlined in the Treatment/Puff TreatmentProcedure. All body wash products were dispensed at 0.7 ml (dosetargeted at 10 μl/cm²). Products were mixed according to the proceduresoutlined in the Test Product Mixing Procedure. Briefly Code C wasprepared by weighing out 10 g of product from individual bottles andthen mixed. A sample of unused Code C was transferred to a jar, sealed,and sent to the Sponsor weekly for analysis. Two of the body washproducts (codes B & E) were swirled dual component products that aresupplied in a single container. A sufficient amount of each swirledproduct for all subjects for one day was dispensed into a dosingcontainer and then stirred with a spatula until the product is wellmixed. The mixed product was drawn into syringes at the 0.7 ml dosage.

Evaluations

At each evaluation, subjects acclimated for a minimum of 30 minutes in aroom with the environment maintained at 70° F.±2 and 30-45% relativehumidity prior to visual grading and non-invasive instrumentalmeasurements being made on their legs.

All evaluations were made in the controlled environment described above.Instrumental measurements were made according to procedures outlined inthe Sponsor's instructions or published guidelines. The same instrumentsand operators were used throughout the study.

Visual Grading

Each subject's lower legs were visually evaluated by a qualified graderfor dryness and redness at baseline (Study Day 8, prior to the firsttreatment) as a prerequisite for qualification into the treatment phase.

The same grader was used throughout the study. Qualifying subjects weregraded at the following 9 additional times during the course of thestudy:

Study Day 8—Baseline and approximately 3 hours post treatment #1;

Study Day 10—approximately 3 hours post treatment #3;

Study Days 12 & 21—approximately 24 hours post treatments #4 and #13 andapproximately 3 hours post treatments #5 and #14;

Study Day 28—approximately 3 hours post treatment #21;

Study Day 29—approximately 24 hours post treatment #21;

Corneometer Skin Capacitance

Non-invasive skin capacitance measurements were taken in duplicate oneach site of the subjects' legs after every visual grading during thestudy using a Corneometer CM825 instrument. Data was recordedelectronically using the Sponsor's direct data entry and data captureprograms. The same instrument and operator were used throughout thestudy

Trans-Epidermal Water Loss (TEWL)

TEWL was measured with the DermaLab® Evaporimeter equipped with dualprobes. Each measurement consists of readings collected for 60 secondswith the mean of the last 20 seconds recorded from both probes (ChannelA and Channel B). One measurement was taken at each treatment site andrecorded on DCF 2 (DermaLab TEWL Measurements Log) on each evaluationday for both probes as Channel A and Channel B, respectively. The sameinstrument and operator were used throughout the study. Thesemeasurements were made according to procedures outlined in the Sponsor'sinstrument SOP or published guidelines. Measurements were taken 8 timesduring the course of the study;

Study Day 8—Baseline;

Study Day 10 —approximately 3 hours post treatment #3;

Study Day 12—approximately 24 hours post treatment #4 and approximately3 hours post treatment #5;

Study Day 21—approximately 24 hours post treatment #13 and approximately3 hours post treatment #14;

Study Day 28—approximately 3 hours post treatment #21;

Study Day 29—approximately 24 hours post treatment #21.

Cutometer Measurements of Elasticity

Non-invasive skin viscoelasticity measurements were taken with aCutometer SEM 575 equipped with an 8 mm probe. Data was recordedelectronically using the data capture program accompanying theinstrument. Two Cutometer instruments were used due to the number ofsubjects enrolled in the study. Subjects were assigned to the sameinstrument throughout the study on the basis of there subject number.The same instruments and operators were used throughout the study. Thesemeasurements were made according to the procedures outlined in theSponsor's instrument SOPs or published guidelines. Measurements weretaken 5 times during the course of the study;

Study Day 8—Baseline;

Study Day 10—approximately 1 hour post treatment #3;

Study Day 12—approximately 1 hour post treatment #5;

Study Day 21—approximately 1 hour post treatment #14;

Study Day 28—approximately 1 hour post treatment #21;

Imaging

Digital images were taken of full length, lower legs. Both left andright outer calves were taken for each subject. Images were capturedwith under both parallel and cross polarized lighting.

The leg imaging system (LIS) uses a combination of two cameras tocapture both study images and repositioning images. Study images arecaptured with a Fuji F2 Pro digital SLR camera with a 60 mm Nikor lens.Repositioning images are captured with a SuperCircuits PC-33C CCD videocamera with a Computar 8.5-40 mm f1.3 CS-mount lens. Using proprietaryimaging software (UltraGrab), both the study and repositioning digitalimages are captured and stored on a portable personal computer whilesimultaneously being backed-up to an external USB hard drive or anothernetworked workstation designated for backup file storage. Imageillumination is provided by 1 JTL Versalight D 1000 flash unit with acolor temperature around 5600 K provides the illumination for the studyimages. The camera and flash unit are mounted onto the imaging platformof the LIS, which also incorporates a fixed color chart used for the“on-the-fly” color calibration and color correction of study images. Achangeable filter holder system is attached in front of the imagingcamera which allows for the selection of the correct combination offilter alignment to capture both parallel and cross polarized images.

To capture an image each subject sat at the end of the imaging systemwith the leg positioning frame. Two leg rests are positioned (one eachnear the ankle and knee) such that the subject can easily place eitherof their outer legs (left or right) against each rest allowing the legto be positioned such that it was in the center of the imaging area. Thesystem was placed in a dedicated room at least 8×8 square feet or acurtained off area of a larger room. One electric circuit and walloutlet provided power to the image capturing system using one outletpower strip and a UPS power backup system. Measurements were taken 6times during the course of the study;

Study Day 8—Baseline;

Study Day 10—approximately 3 hours post treatment #3;

Study Day 12—approximately 3 hours post treatment #5;

Study Day 21—approximately 3 hours post treatment #14;

Study Day 28—approximately 3 hours post treatment #21;

Study Day 29—approximately 24 hours post treatment #21

Tape Stripping

Tape stripping was performed throughout the study for dry skin sampling.D-Squames was always collected following all other evaluations scheduledto take place at the same time point. Clinical assistants woredisposable gloves while collecting D-Squames. At each collection timepoint a series of 6 D-Squames were used to sample the same spot withinthe treatment area. The technician used forceps to place a D-Squamessampling disc toward the edges of each site (away from the region beingevaluated by other instrumentation) and applied pressure using theD-Squames disc applicator (push the D-Squames applicator down and thenrelease). The technician removed the sampling disc with forceps andplaced the disc into a pre-labeled 12 well culture plate. Each subjecthad two 12 well culture plates for sampling disc collection; one foreach leg. Wells 1-6 of each plate were for the site nearest the knee,while wells 7-12 were used for the site nearest the ankle. D-Squamessample plates were placed in shipping boxes with labels corresponding tothe subjects' samples enclosed and placed in a cooler with dry ice. Thesamples were couriered to the Sponsor's designee once all samples forthe day have been collected. D-Squames was collected 4 times at thefollowing time points:

Study Day 8—Baseline;

Study Day 12—approximately 24 hours post treatment #4;

Study Day 21—approximately 24 hours post treatment #13;

Study Day 29—approximately 24 hours post treatment #21;

References: Ertel, K. D., Neumann, P. B., Hartwig, P. M., Rains, G. Y.,and Keswick, B. H., Leg Wash protocol to assess the skin moisturizationpotential of personal cleansing products. Int. J. Cosmet. Sci. 21:383-397 (1999); Fitzpatrick, T. B., The validity and practicality ofsun-reactive skin types I through VI. Arch. Dermatology, 124: 869-871(1988).

Cytokine, Keratin and Soluble Protein Analyses

Samples were collected for analysis using D-Squame Tape Strips. D-Squametapes were applied on the site of interest (Scalp, Leg, Face, Underarm,Forearm) with constant pressure/time, and removed to collect samples ofthe stratum corneum. Alternative sampling methods using Sebutape and CupScrubs can also be accommodated. Tape strip samples were placed in a 12well plate under frozen conditions (−80° C.) until analysis. Tapesamples were extracted for analysis by placing the tapes inside apolypropylene tube (2 ml) and adding extraction buffer (PBS, pH 7.4,0.04% SDS, Protease Inhibitors) and sonicating for 30 min at 4° C. Thesamples were then centrifuged to remove any insoluble material and thesupernatant is transferred into two deep well plates.

Supernatant samples for Cytokine/keratin analysis were fortified with2.0% Bovine Serum Albumin (BSA) before freezing. The remainingsupernatants were transferred to a second deep well plate for SolubleProtein analysis. Samples were analyzed for Cytokines (IL-1^(α), IL-1ra,IL-8) and Skin analytes (Human Serum Albumin, Keratin 1, 10, 11) usingvalidated Millipore™ Multiplex immunoassay methods with a Bio-PlexProtein Array Reader system. Soluble protein determinations of thesupernatants were performed using the Pierce BCA™ Protein assay kit withthe aliquot designated for soluble protein using a validated method. Thevalues obtained for soluble proteins were used to normalize the Cytokineand Keratin data. Cytokine and Skin analyte concentrations were reportedas pg/mL or ng/mL and the soluble proteins were reported as μg/mL.Methods have been validated to demonstrate accuracy, precision, benchtop stability, freeze thaw stability, short and long term storagestability of the extracts. Extraction efficiency of the methods havebeen shown to be >70% and reproducible with a single extraction of thetape strips.

Expected Biomarker Outcome for Endpoints Biomarkers Rationale BenefitBenefit Stratum Total Protein More ↓ Strengthening Corneum cohesivenessstrateum Cohesiveness in healthy corneum stratum Improving skin corneum.barrier. Less cohesiveness in damaged skin. Differentiation Keratin 1,10 Higher dif- ↑ Improving skin 11 ferentiation health in normal/healthy skin. Irritation/ Cytokines Elevated in ↓ Reducing skinInflammation IL-1^(α), diseased/ irritation. IL-1ra, IL-8 irritatedskin.Keratin 1, 10, 11 Results: The results of Keratin 1, 10, 11 werenormalized to total soluble protein. The results are plotted below. Asignificant increase of normalized Keratin 1, 10 11 as compared to watercontrol at day 7 (100% increase) was observed. The normalized Keratin 1,10, 11 level is further increased to 150% vs. water at day 14 and 22.The data is consistent with literature reports that dry skin dry skin isa condition characterized by hyperproliferation and decreaseddifferentiation. (See Engeke, Jensen, Ekanayake-Mudiyanselage andProksch “Effects of xerosis and aging on epidermal proliferation anddifferentiation”, Br. J. Dermatology, 137: 219-225 (1997).)Total Protein Results: The results of the total protein from sixconsecutive tape strips as measured by SquameScan 850 were obtained.Treatment according to the variable lipid method showed improvedcohesiveness at day 7.0, 14.0, and 22.0 measurement points vs. watercontrol.

Example 3 Improvements in Skin Elasticity and Cohesion from a PetrolatumDepositing Bodywash

Aging skin is frequently characterized by an increase in dryness andsubsequent flaking, as well as a general loss of elasticity. Dailyactivities such as bathing can exacerbate some of these issues,particularly if skin drying products such as soap are used. Whilemoisturizing bodywashes are readily available in the market, few purportto make improvements in skin condition beyond skin dryness.

Objective

In an effort to improve the overall condition, health and viability ofaging skin, we have developed a petrolatum depositing bodywash that isaesthetically pleasing to use and will deliver benefits beyond typicalmoisturization.

Method

Standard Leg Controlled-Application Test (LCAT) methodology was used.Treatment was conducted over a 3 week period; women with dry leg skinhad their legs washed once daily with the randomly assigned body washproducts and water alone treatment as control (˜50 per treatment).Typical moisturization measures were taken, including expert drynessgrading, corneometer and TEWL.

Non-invasive skin viscoelasticity measurements were taken with aCutometer SEM 575. Tape-strip analysis of biomarkers was also conductedto gain insight into how the product affected the skin health andintegrity. Six successive D-squame tapes were taken from virgin areaswithin each treatment site at baseline and at the end of each treatmentweek. The strips were then analyzed for total protein with a SquameScan850 as a measure of stratum corneum cohesiveness. The method is based ona well established D-Squame tape strip procedure. Tape strip samples aresubsequently extracted in appropriate buffer solution by sonicationfollowed by centrifugation. The resulting supernatant samples areanalyzed for relevant skin biomarkers (total proteins, cytokines, andkeratin) by validated analytical methods (Multiplex ELISA and LC/MS/MS).

Results

Results indicate that the body wash delivers significant improvements inall standard moisturization measures (dryness grades, corneometerhydration, and TEWL). For the first time in the rinse-off context, theresults show significant improvement in skin elasticity as compared tothe water treatment control. The total protein results further revealsignificant improvement in stratum corneum cohesiveness. Taken together,these findings support the conclusion that the petrolatum depositingbodywash improves the overall condition of skin.

Example 4 Test of Inventive Composition Example A

The following test of Inventive Composition Example A furtherdemonstrates the benefits of articles, methods, and/or compositions usedin accordance with the present invention.

Step A) Preconditioning Phase Procedure

-   -   During preconditioning, enrolled subjects used a bar of Olay®        with no exfoliating beads provided by the test facility in place        of their usual product(s) for bathing and showering. They        continued to use this product throughout their participation.

Step B). Treatment Phase Procedure

-   -   Before initial grading on Study Day 8, test facility personnel        marked off the leg application areas [two 70 cm² areas (7 cm        across×10 cm down)] on the outer aspect of the subjects' lower        legs using a template and laboratory marking pen (corner        brackets are sufficient to delineate each area). Trained        clinical assistants treated each subject's legs according to the        procedure outlined in the Treatment Procedure. In general, the        following should be noted:

TREATMENT PROCEDURE:

-   -   Begin with the LEFT leg:    -   1. A Clinical Assistant wets the treatment area for 5 seconds        with 95-100° F. running tap water.    -   2. The Clinical Assistant applies the test product assigned to        that site, using the appropriate procedure as follows:    -   “No Treatment” (water only):        -   No product is applied to this site. Wait approximately 10            seconds, then continue as below with Step #3.        -   [The “No Treatment” site is wetted initially (#1), rinsed            (#5), and dried (#6) per the normal wash procedure. The site            is timed for the 90 sec. “residence” (#3) but does not have            product applied nor undergo any of the physical manipulation            (i.e., rubbing with fingers or implement).]    -   Body Wash Products:        -   While holding the appropriately labeled puff in one hand,            wet the puff for 5 seconds under the running tap, then allow            the excess water to drain off the puff for 10 seconds            without shaking or squeezing the puff.        -   Dispense 0.7 ml of body wash product from the syringe onto            the center of the treatment area.        -   Place the wet puff over the dispensed product and gently rub            the puff back and forth within the appropriate site for 10            seconds.    -   3. The lather (or water only) remains on the application site        for 90 seconds.    -   4. When the residence time for a particular application site has        expired, the Clinical Assistant will rinse the site for 15        seconds under a running tap, taking care not to rinse the        adjacent sites.    -   5. After the application area has been rinsed, the Clinical        Assistant gently pats the area dry with a disposable paper        towel.    -   6. Using the appropriate treatments, this entire procedure        (#1-5) is repeated on the lower site on the left leg before        conducting the entire procedure (#1-5) on the right leg.

PUFF TREATMENT PROCEDURE

-   -   1. While holding the appropriately labeled puff in one hand, wet        the puff for 5 seconds under the running tap, then allow the        excess water to drain off the puff for 10 seconds without        shaking or squeezing the puff.    -   2. Dispense 9.3 ml of appropriate body wash product onto the        puff in a broad circular pattern.    -   3. Hold puff in one hand. Squeeze puff until you just feel the        core. Do 10 rotations forward alternating hands, then repeat in        the opposite direction for 10 rotations alternating hands, for a        total of 20 rotations    -   4. Following the wash, while holding the puff in one hand, rinse        the puff for 20 seconds under the running tap, then allow the        excess water to drain off then hang to dry.

Step C). Evaluations

-   -   At each evaluation, subjects were acclimated for a minimum of 30        minutes in a room with the environment maintained at 70° F.±2        and 30-45% relative humidity prior to visual grading and        non-invasive instrumental measurements being made on their legs.        All evaluations were made in the controlled environment        described above.    -   1. Visual Grading:    -   Each subject's lower legs were visually evaluated by a qualified        grader for dryness at baseline (Study Day 8, prior to the first        treatment) as a prerequisite for qualification into the        treatment phase. The minimum entrance criteria are >2.5 in        initial dryness at the start of the treatment phase (Step B).    -   2. Cutometer Measurement of Skin Elasticity    -   The first cutometer measurement was performed before the initial        product treatment phase as baseline. The second set of cutometer        measurement was made at 90 mins after the seventh product        treatment. All non-invasive skin viscoelasticity measurements        were taken with a Cutometer® SEM 575 (Courage & Khazaka,        Electronic GmbH, Koeln, Germany) equipped with an 8 mm probe at        200 mbar pressure. The same instruments and operators were used        throughout the study. The following elastic parameters are        typically used: elastic extension U_(e), elastic recovery U_(r),        and elasticity R₇.    -   The cutometer's operating principles and applications are        described in reference below: A. O, Barel, W. Courage, P.        Clarys; Sunction Method for Measurement of Skin Mechnical        Properties, the Cutometer®; Handbook of Non-Invasive Methods and        the Skin, J. Serup G. B. E. Jemec, 1995; 335-340.    -   3. Tape Stripping Procedure and Total Stratum Corneum Protein        Measurement    -   A first set of tape stripping was performed before the initial        product treatment phase as baseline. The second set of tape        stripping was performed at 24 hours after the sixth product        treatment. Clinical assistants wore disposable gloves while        collecting D-Squames®. At each collection time point a series of        6 D-Squames were used to sample the same spot within the        treatment area. The technician used forceps to place a D-Squame®        sampling disc toward the edges of each site (away from the        region being evaluated by other instrumentation) and apply        pressure using the D-Squame disc applicator (push the D-Squame        applicator down and then release). The technician then removed        the sampling disc with forceps and placed the disc into a        pre-labeled 12 well culture plate. Each subject had two 12 well        culture plates for sampling disc collection; one for each leg.    -   The total stratum corneum proteins are analyzed by infrared        densitometry (model number SquameScan® 850A, Heiland Electronic,        Wetzlar, Germany). The results are reported as protein        absorptance at 850 nm. The method is described in reference: R.        Voegeli, J. Heiland, S. Doppler, A. V. Rawlings and T. Schreier;        Efficient and simple quantification of stratum corneum proteins        on tape strippings by infrared densitometry, Skin Research and        Technology 2007; 13; 242-251.

Step D). Calculation of Skin Elasticity Improvement Index and StratumCorneum Cohesiveness Improvement Index

-   -   1) Calculation of Skin Elasticity Improvement Index        -   a) Elastic Extension (U_(e)) Improvement Index is calculated            as:

[(U_(e))^(P) _(end)−(U_(e))^(c) _(end)]/(U_(e))^(c)_(end)*100−[(U_(e))^(P) _(ini)−(U_(e))^(c) _(ini)]/(U_(e))^(c)_(ini)*100

-   -   wherein        -   (U_(e))^(c) _(ini) is the initial elastic extension            parameter at the beginning of the water control leg;        -   (U_(e))^(P) _(ini) is the initial elastic extension            parameter at the beginning of the test product leg;        -   (U_(e))^(c) _(end) is the final elastic extension parameter            at the end of the water control leg;        -   (U_(e))^(P) _(end) is the final elastic extension parameter            at the end of the test product leg.        -   b) Elastic Recovery (U_(r)) Improvement Index is calculated            as:

[(U_(r))^(P) _(end)−(U_(r))^(c) _(end)]/(U_(r))^(c)_(end)*100−[(U_(r))^(P) _(ini)−(U_(r))^(c) _(ini)]/(U_(r))^(c)_(ini)*100

-   -   wherein        -   (U_(r))^(c) _(ini) is the initial elastic recovery parameter            at the beginning of the water control leg;        -   (U_(r))^(P) _(ini) is the initial elastic recovery at the            beginning of the test product leg;        -   (U_(r))^(c) _(end) is the final elastic recovery at the end            of the water control leg;        -   (U_(r))^(P) _(end) is the final elastic recovery at the end            of the test product leg.        -   c) Elasticity (R₇) Improvement Index is calculated as:

[(R₇)^(P) _(end)−(R₇)^(c) _(end)]/(R₇)^(c) _(end)*100−[(R₇)^(P)_(ini)−(R₇)^(c) _(ini)]/(R₇)^(c) _(ini)*100

-   -   wherein        -   (R₇)^(c) _(ini) is the initial elasticity at the beginning            of the water control leg;        -   (R₇)^(P) _(ini) is the initial elasticity at the beginning            of the test product leg;        -   (R_(7r))^(c) _(end) is the final elasticity at the end of            the water control leg;        -   (R₇)^(P) _(end) is the final elasticity at the end of the            test product leg.    -   2) Calculation of Stratum Corneum Cohesiveness Improvement Index        -   a) Stratum Corneum Cohesiveness Improvement Index is            calculated as:

[(Protein)^(C) _(end)−(Protein)^(P) _(end)]/(Protein)^(C)_(end)*100−[(Protein)^(C) _(ini)−(Protein)^(P) _(ini)]/(Protein)^(C)_(ini)*100

-   -   wherein        -   (Protein)^(c) _(ini) is the sum of initial protein            absorption of tape 1 to tape 6 at the beginning of the water            control leg;        -   (Protein_(e))^(P) _(ini) is the sum of initial protein            absorption of tape 1 to tape 6 at the beginning of the test            product leg;        -   (Protein)^(c) _(end) is the sum of final protein absorption            of tape 1 to tape 6 at the end of the water control leg;        -   (Protein)^(P) _(end) is the sum of final protein absorption            of tape 1 to tape 6 at the end of the test product leg.    -   3) Calculation of Keratine 1, 10, 11 Improvement Index        -   Keratin 1, 10, 11 Improvement Index is calculated as:

[(Keratin)^(C) _(end)−(Keratin)^(P) _(end)]/(Keratin)^(C)_(end)*100−[(Keratin)^(C) _(ini)−(Keratin)^(P) _(ini)]/(Keratin)^(C)_(ini)*100

-   -   wherein        -   (Keratin)^(c) _(ini) is the initial Keratin 1, 10, 11            normalized to total soluble protein at the beginning of the            water control leg;        -   (Keratin)^(P) _(ini) is the initial Keratin 1, 10, 11            normalized to total soluble protein at the beginning of the            test product leg;        -   (Keratin)^(c) _(end) is the final Keratin 1, 10, 11            normalized to total soluble protein at the end of the water            control leg;        -   (Keratin)^(P) _(end) is the final Keratin 1, 10, 11            normalized to total soluble protein at end of the test            product leg.            Results of Inventive Composition Example A vs. Water Control

Inventive p value Example A (base size n = 50) a) Skin Elastic Extension(Ue) 16 p = 0.003 Improvement Index b) Skin Elastic Recovery (Ur) 21 p =0.0004 Improvement Index c) Skin Elasticity (R7) Improvement 4 p = 0.05Index d) Stratum Corneum Cohesiveness 23 p < 0.0001 Improvement Index e)Keratin Improvement Index 172 p < 0.0001

IV. Personal Care Articles and Personal Care Compositions

The present invention contemplates use of personal care compositions andarticles comprising personal care compositions. In some embodiments,personal care articles for dispensing a personal care compositionscomprises a single chamber package and a personal care article. It willbe appreciated that other embodiments of personal care articles andpersonal care compositions are contemplated for use according to theinvention, and the following descriptions regarding possible embodimentsis non-limiting.

Single chamber package comprises a dispensing orifice, a first zoneproximal to the dispensing orifice, a second zone medial to thedispensing orifice, and a third zone distal to the dispensing orifice.The personal care article comprises a first personal care composition, asecond personal care composition and a third personal care composition.The first personal care composition is substantially within the firstzone and comprises a first concentration of a hydrophobic benefitmaterial. The second personal care composition is substantially withinthe second zone and comprises a second concentration of a hydrophobicbenefit material. The third personal care composition is substantiallywithin the third zone and comprises a third concentration of ahydrophobic benefit material. The second concentration is greater thanthe first concentration and the third concentration of the hydrophobicbenefit material. The first personal care composition is capable ofbeing substantially dispensed prior to the second personal carecomposition and the third personal care composition. The second personalcare composition is capable of being substantially dispensed prior tothe third personal care composition.

The personal care article used in accordance with the present invention,in most embodiments, is statically stable. In most embodiments, thepersonal care article used in accordance with the present invention isdynamically stable according to the Dynamic Stability Shipping Methoddisclosed in the Test Methods below.

In some embodiments, the first personal care composition is in physicalcontact with the second personal care composition within the singlechamber package. The second personal care composition, in anotherembodiment, is in physical contact with the third personal carecomposition within the single chamber package.

In one embodiment, the first zone, second zone and/or third zone of thepresent invention comprises from about 10% to about 70%, by volume, ofthe package. The first zone, second zone and/or third zone of thepresent invention comprise from about 10% to about 60%, from about 10%to about 50%, from about 10% to about 40%, from about 10% to about 30%,from about 10% to about 20%, by volume, of the package. In otherembodiments, the first zone, second zone and/or third zone of thepresent invention comprises from about 20% to about 70%, from about 20%to about 60%, from about 20% to about 50%, from about 20% to about 40%,from about 20% to about 30%, by volume, of the package. In otherembodiments, the first second and/or third zone of the present inventioncomprises from about 30% to about 70%, from about 30% to about 60%, fromabout 30% to about 50%, from about 30% to about 40%, by volume, of thepackage.

The personal care article used in accordance with the present inventioncomprises a single chamber package can contain any number or zones andcompositions, such as for example, four zones and four compositions,five zones and five compositions, six zones and six compositions, twelvezones and twelve compositions, and so on. Each of these compositions iscapable of substantially dispensing prior to the composition before itin a substantially sequential manner. For example, the fourth personalcare composition substantially within the fourth zone is capable ofdispensing prior to the fifth personal care composition within the fifthzone, etc. In some embodiments, a dual-chamber delivery article havingside-by-side chambers with a control valve or cap to regulate dispensingfrom each chamber may be used. In other embodiments, a dual-chamberdelivery article with end-to-end chambers may be selected, where productis dispensed separately from each chamber. In yet other embodiments, akit of two or more separate bottles that may nest or stack or otherwiseinter-fit may be used for dispensing the personal care compositions.

The personal care article used in accordance with the present inventionis filled to comprise a headspace. In some embodiments, the personalcare article used in accordance with the present invention comprises aheadspace that is less than 10%, is less than 6%, less than 5% and lessthan 4%. In other embodiments, the personal care article used inaccordance with the present invention comprises a headspace that is lessthan 3%, less than 2% and less than 1%.

In another aspect, each personal care composition comprises a dye,colorant or the like, such that each personal care composition is adistinct color or hue. For example, the first personal care compositionis a yellow color, the second personal care composition is an orangecolor and the third personal care composition is a purple color.

The amount or concentration of hydrophobic benefit materials in thefirst personal care composition, second personal care composition andthird personal care composition are usually formulated, by weight of thecomposition, at less than about 75%, less than about 65%, less thanabout 60%, less than about 60%, less than about 55%, less than about50%, less than about 45%, less than about 40%, less than about 35%, lessthan about 30%, less than about 25%, less than about 20%, less thanabout 10%, less than about 5%, less than about 4%, less than about 3%,less than about 2%, less than about 1%. The first personal carecomposition, second personal care composition and third personal carecomposition comprises from about 1.0% to about 60%, from about 5% toabout 60%, from about 10% to about 50%, from about 20% to about 45%, byweight of the personal care composition, of a hydrophobic benefitmaterial.

In some embodiments, the first concentration can comprise from about 10%to less than about 50% or, from about 10% to about 40%, by weight of thefirst personal care composition. The first concentration of hydrophobicmaterial, in other embodiments, comprise from about 15% to less than 45%or 15% to less than 35% by weight of the first personal carecomposition, of hydrophobic benefit material. The first concentration,in some embodiments, comprise from about 20% to about 40% and from about25% to about 40%, by weight of the first personal care composition.

In some embodiments, the second concentration comprises from greaterthan 30% to about 70%, greater than about 35% to about 65%, by weight ofthe second personal care composition, of hydrophobic benefit material.In another embodiment, the second concentration comprises from about 40to about 60% and about 55% by weight of the second personal carecomposition.

In some embodiments, the third concentration can comprise from about 10%to less than about 50% or, from about 10% to about 40%, by weight of thethird personal care composition. The third concentration of hydrophobicmaterial, in other embodiments, comprise from about 15% to less than 45%or 15% to less than 35% by weight of the third personal carecomposition, of hydrophobic benefit material. The third concentration,in some embodiments, comprise from about 20% to about 40% and from about25% to about 40%, by weight of the third personal care composition.

In one embodiment, the first personal care composition, second personalcare composition and third personal care composition used in accordancewith the present invention are multi-phase compositions and comprise oneof more phases or one or more of the components described in the phasesbelow:

The personal care compositions used in accordance with the presentinvention comprise a benefit phase or benefit phase components. Thebenefit phase in the present invention, in most embodiments, isanhydrous and is substantially free of water. In some embodiments, thebenefit phase is substantially free or free of surfactant.

Hydrophobic benefit materials suitable for use in the present inventiontypically have a Vaughan Solubility Parameter of from about 5(cal/cm³)^(1/2) to about 15 (cal/cm³)^(1/2), as defined by Vaughan inCosmetics and Toiletries, Vol. 103. The Vaughan Solubility Parameter(VSP) as used herein is a parameter used to define the solubility ofhydrophobic materials. Vaughan Solubility parameters are well known inthe various chemical and formulation arts and typically have a range offrom 5 to 25. Non-limiting examples of hydrophobic benefit materialshaving VSP values ranging from about 5 to about 15 include thefollowing: Cyclomethicone 5.92, Squalene 6.03, Petrolatum 7.33,Isopropyl Palmitate 7.78, Isopropyl Myristate 8.02, Castor Oil 8.90,Cholesterol 9.55, as reported in Solubility, Effects in Product,Package, Penetration and Preservation, C. D. Vaughan, Cosmetics andToiletries, Vol. 103, October 1988.

The hydrophobic benefit materials for use in the benefit phase of thecomposition have a preferred rheology profile as defined by Consistencyvalue (k) and Shear Index (n). The term “Consistency value” or “k” asused herein is a measure of lipid viscosity and is used in combinationwith Shear Index, to define viscosity for materials whose viscosity is afunction of shear. The measurements are made at 35° C. and the units arepoise (equal to 100 cps). The term “Shear Index” or “n” as used hereinis a measure of lipid viscosity and is used in combination withConsistency value, to define viscosity for materials whose viscosity isa function of shear. The measurements are made at 35° C. and the unitsare dimensionless. Consistency value (k) and Shear Index (n) are morefully described in the Test Methods below. Preferred Consistency valueranges are 1-10,000 poise (1/sec)^(n-1), typically 10-2000 poise(1/sec)^(n-1) and more typically 50-1000 poise (1/sec)^(n-1). ShearIndex ranges are 0.1-0.8, typically 0.1-0.5 and more typically 0.20-0.4.These preferred rheological properties are especially useful inproviding the personal cleansing compositions with improved depositionof benefit agents on skin.

In one embodiment, the benefit phase is comprised of the hydrophobicbenefit materials selected from the group consisting of petrolatum,lanolin, derivatives of lanolin (e.g. lanolin oil, isopropyl lanolate,acetylated lanolin, acetylated lanolin alcohols, lanolin alcohollinoleate, lanolin alcohol riconoleate) hydrocarbon oils (e.g. mineraloil) natural and synthetic waxes (e.g. micro-crystalline waxes,paraffins, ozokerite, lanolin wax, lanolin alcohols, lanolin fattyacids, polyethylene, polybutene, polydecene, pentahydrosqualene)volatile or non-volatile organosiloxanes and their derivatives (e.g.dimethicones, cyclomethicones, alkyl siloxanes, polymethylsiloxanes,methylphenylpolysiloxanes), natural and synthetic triglycerides (e.g.castor oil, soy bean oil, sunflower seed oil, maleated soy bean oil,safflower oil, cotton seed oil, corn oil, walnut oil, peanut oil, oliveoil, cod liver oil, almond oil, avocado oil, palm oil, sesame oil) andcombinations thereof. In one aspect, at least about 50% by weight of thehydrophobic benefit materials are selected from the groups ofpetrolatum, mineral oil, paraffins, polyethylene, polybutene,polydecene, dimethicones, alkyl siloxanes, cyclomethicones, lanolin,lanolin oil, lanolin wax. In one embodiment, the remainder of thehydrophobic benefit material is selected from: isopropyl palmitate,cetyl riconoleate, octyl isononanoate, octyl palmitate, isocetylstearate, hydroxylated milk glyceride and combinations thereof. Thebenefit phase of the personal care composition, in some embodiments,comprises a combination of petrolatum and mineral oil.

In some embodiments, the personal care composition used in accordancewith the present invention comprises a surfactant phase. The personalcare composition typically comprises from about 1% to about 100%, byweight of the composition; from about 5% to about 85%; by weight of thecomposition, from about 10% to 80%, by weight of the composition; fromabout 20 to 70%, by weight of the composition; from about 25% to 60%, byweight of the composition, from about 30% to about 50%, by weight of thecomposition, of a surfactant phase.

In some embodiments, the surfactant phase comprises a structured domainthat is comprised of a mixture of surfactants. The presence ofstructured domain enables the incorporation of high levels ofhydrophobic benefit materials in a separate phase which is notemulsified within composition. In one aspect, the structured domain inthe composition is characterized as, or is, an opaque structured domain.In one aspect, the opaque structured domain is characterized as, or is,a lamellar phase. The lamellar phase produces a lamellar gel network.The lamellar phase provides resistance to shear, adequate yield tosuspend particles and droplets and at the same time provides long termstability, since it is thermodynamically stable. The lamellar phasetends to have a higher viscosity thus minimizing the need for viscositymodifiers.

In one aspect, the surfactant phase comprises a domain that is comprisedof a mixture of surfactants and is a micellar phase. A micellar phase isoptically isotropic. Micelles are approximately spherical in shape.Other shapes such as ellipsoids, cylinders, and bilayers are alsopossible. In one aspect, the micellar phase is structured to enhanceviscosity and to suspend particles. This can be accomplished usingviscosity modifiers such as those defined below as water structurants.

In some embodiments, the surfactant phase comprises a surfactantcomponent which comprises of a mixture of surfactants includinglathering surfactants or a mixture of lathering surfactants. Thesurfactant phase comprises surfactants suitable for application to themammalian skin or hair and is compatible with water and the otheringredients of the composition used in accordance with the presentinvention. These surfactants include anionic, nonionic, cationic,zwitterionic, amphoteric, soap, or combinations thereof. Typically,anionic surfactant comprises at least 40% of the surfactant component.The personal care composition, in some embodiments, comprises thesurfactant component at concentrations ranging from about 2% to about40%, from about 4% to about 25%, about 1% to about 21%, about 3 to 15%,by weight of the composition, of the surfactant component.

Suitable surfactants are described in McCutcheon's, Detergents andEmulsifiers, North American edition (1986), published by alluredPublishing Corporation; and McCutcheon's, Functional Materials, NorthAmerican Edition (1992); and in U.S. Pat. No. 3,929,678 issued toLaughlin, et al on Dec. 30, 1975.

Preferred linear anionic surfactants for use in the surfactant phase ofthe personal care composition include ammonium lauryl sulfate, ammoniumlaureth sulfate, sodium lauryl sulfate, sodium laureth sulfate,potassium laureth sulfate, sodium lauryl sarcosinate, sodium lauroylsarcosinate, lauryl sarcosine, cocoyl sarcosine, ammonium cocoylsulfate, potassium lauryl sulfate, and combinations thereof.

Branched anionic surfactants and monomethyl branched anionic surfactantssuitable for the present invention are described in a commonly ownedU.S. Publication No. 60/680,149 entitled “Structured Multi-phasedPersonal Cleansing Compositions Comprising Branched Anionic Surfactants”filed on May 12, 2005 by Smith, et al. Branched anionic surfactantsinclude but are not limited to the following surfactants: sodiumtrideceth sulfate, sodium tridecyl sulfate, sodium C₁₂₋₁₃ alkyl sulfate,and C₁₂₋₁₃ pareth sulfate and sodium C₁₂₋₁₃ pareth-n sulfate.

In one aspect of the personal care compositions used in accordance withthe present invention comprise an amphoteric surfactant, a zwitterionicsurfactant and combinations thereof. In one embodiment, the personalcare composition comprises at least one amphoteric surfactant.Amphoteric surfactant suitable for use in the present invention includethose that are broadly described as derivatives of aliphatic secondaryand tertiary amines in which the aliphatic radical can be straight orbranched chain and wherein one of the aliphatic substituents containsfrom about 8 to about 18 carbon atoms and one contains an anionic watersolubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, orphosphonate. Examples of compounds falling within this definition aresodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminopropanesulfonate, sodium lauryl sarcosinate, N-alkyltaurines such as the oneprepared by reacting dodecylamine with sodium isethionate according tothe teaching of U.S. Pat. No. 2,658,072, N-higher alkyl aspartic acidssuch as those produced according to the teaching of U.S. Pat. No.2,438,091, and the products described in U.S. Pat. No. 2,528,378. In oneaspect, the personal care composition comprises an amphoteric surfactantthat is selected from the group consisting of sodium lauroamphoacetate,sodium cocoamphoactetate, disodium lauroamphoacetate disodiumcocodiamphoacetate, and combinations thereof. Moreover, Amphoacetatesand diamphoacetates are also used in some embodiments of the presentinvention.

Zwitterionic surfactants suitable for use include those that are broadlydescribed as derivatives of aliphatic quaternary ammonium, phosphonium,and sulfonium compounds, in which the aliphatic radicals can be straightor branched chain, and wherein one of the aliphatic substituentscontains from about 8 to about 18 carbon atoms and one contains ananionic group, e.g., carboxy, sulfonate, sulfate, phosphate, orphosphonate. Zwitterionic surfactants suitable for use in the personalcare composition include alkyl betaines, including cocoamidopropylbetaine.

The personal care composition used in accordance with the presentinvention is typically free of alkyl amines and alkanolamide to ensuremildness of the composition to the skin.

An electrolyte can be added per se to the personal care composition orit can be formed in situ via the counterions included in one of the rawmaterials. The electrolyte typically includes an anion comprisingphosphate, chloride, sulfate or citrate and a cation comprising sodium,ammonium, potassium, magnesium or combinations thereof. Some preferredelectrolytes are sodium chloride, ammonium chloride, sodium or ammoniumsulfate. The electrolyte is typically added to the surfactant phase ofthe composition in the amount of from about 0.1% to about 6%; from about1% to about 5%, more typically from about 2% to about 4%, more typicallyfrom about 3% to about 4%, by weight of the personal care composition.

In one embodiment, the first personal care composition comprise a firstconcentration of surfactant, the second personal care compositioncomprises a second concentration of surfactant and the third personalcare composition comprises a third concentration of surfactant. Thefirst concentration of surfactant is different from the secondconcentration of surfactant and the third concentration of surfactant,in some embodiments. In one aspect, the first personal care compositionhas a first concentration of surfactant that is a greater that thesecond concentration of surfactant in the second personal carecompositions and is the same as or greater than the third concentrationof surfactant in the third personal care compositions. In one aspect,the first personal care composition has a lower concentration ofsurfactant than the second and the third personal care compositions.

In some embodiments, the personal care compositions used in accordancewith the present invention comprise a structured aqueous phase. Thestructured aqueous phase, in one embodiment, comprises a waterstructurant and water. The structured aqueous phase has a pH in therange from about 5 to about 9.5, or in one aspect have a pH of about 7.In one embodiment, the structured aqueous phase is hydrophilic. In oneaspect, the structured aqueous phase is a hydrophilic, non-latheringgelled water phase.

In some embodiments, the structured aqueous phase comprises less thanabout 5%, less than about 3%, less than about 1%, by weight of thestructured aqueous phase, of a surfactant component. In one aspect, thestructured aqueous phase is free of lathering surfactants in thecomposition. In one embodiment, the structured aqueous phase of thepresent invention comprises from about 30% to about 99%, more than about50%, more than about 60%, more than about 70%, more than about 80%, byweight of the structured aqueous phase, of water.

In one embodiment, the structured aqueous phase comprises a waterstructurant. The water structurant is selected from the group consistingof inorganic water structurants (e.g. silicas, polyacrylates,polyacrylamides, modified starches, crosslinked polymeric gellants,copolymers) charged polymeric water structurants (e.g. Acrylates/VinylIsodecanoate Crosspolymer available, STABYLEN 30® available from 3VSIGMA S.P.A of Bergamo Italy), Acrylates/C10-30 Alkyl AcrylateCrosspolymer (e.g. PEMULEN™ TR1 and TR2 polymers available fromNOVEON®), Carbomers, Ammonium Acryloyldimethyltaurate/VP Copolymer (e.g.Aristoflex® AVC available from Clariant), AmmoniumAcryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer (e.g.ARISTOFLEX® HMB available from Clariant), Acrylates/Ceteth-20 ItaconateCopolymer (e.g. STRUCTURE® 3001 available from National Starch),Polyacrylamide (e.g. SEPIGEL™ 305 available from SEPPIC), water solublepolymeric structurants (e.g. cellulose gums and gel, and starches),associative water structurants (e.g. xanthum gum, gellum gum, pectins,alginates such as propylene glycol alginate), and combinations thereof.In some embodiments, the structured aqueous phase comprises from about0.1% to about 30%, from about 0.5% to about 20%, from about 0.5% toabout 10%, and from about 0.5% to about 5%, by weight of the structuredaqueous phase, of a water structurant. In some embodiments, a waterstructurant for the structured aqueous phase has a net cationic charge,net anionic charge, or neutral charge.

While not essential for the purposes of the present invention, thenon-limiting list of optional materials, illustrated hereinafter aresuitable for use in personal care compositions, and may be incorporatedin certain embodiments, for example to assist or enhance cleansingperformance, for treatment of the skin, or to modify the aesthetics ofthe personal care composition. Optional materials useful in the productsherein are described by their cosmetic and/or therapeutic benefit ortheir postulated mode of action or function. These descriptions arenon-limiting and made for the sake of convenience because it isunderstood that these materials can provide more than one benefit,function or operate via more than one mode of action. The precise natureof these optional materials, and levels of incorporation thereof, willdepend on the physical form of the composition and the nature of thecleansing operation for which it is to be used. The amount of optionalmaterials in compositions are usually formulated, by weight of thecomposition, at less than about less than about 6%, less than about 5%,less than about 4%, less than about 3%, less than about 2%, less thanabout 1%, less than about 0.5%, less than about 0.25%, less than about0.1%, less than about 0.01%, less than about 0.005%.

In some embodiments of the present invention, comprise optionalingredients, which are selected from the group consisting of thickeningagents, low density microspheres (e.g. EXPANCEL® microspheres availablefrom 091 WE40 d24, Akzo Nobel and others described in commonly owned andassigned U.S. Patent Publication No. 2004/0092415A1 published on May 13,2004), preservatives, antimicrobials, fragrances, chelators (e.g. suchas those described in U.S. Pat. No. 5,487,884 issued to Bisset et al.),sequestrants, vitamins (e.g. Retinol), vitamin derivatives (e.g.tocophenyl actetate, niacinamide, panthenol), sunscreens, desquamationactives (e.g. such as those described in U.S. Pat. Nos. 5,681,852 and5,652,228 issued to Bisset), anti-wrinkle/anti-atrophy actives (e.g.N-acetyl derivatives, thiols, hydroxyl acids, phenol), anti-oxidants(e.g. ascorbic acid derivatives, tocophenol), skin soothing agents/skinhealing agents (e.g. panthenoic acid derivatives, aloe vera, allantoin),skin lightening agents (e.g. kojic acid, arbutin, ascorbic acidderivatives), skin tanning agents (e.g. dihydroxyacteone), polymericphase structurant (e.g. naturally derived polymers, synthetic polymers,crosslinked polymers, block copolymers, copolymers, hydrophilicpolymers, nonionic polymers, anionic polymers, hydrophobic polymers,hydrophobically modified polymers, associative polymers, and oligomers);a liquid crystalline phase inducing structurant (e.g. trihydroxystearinavailable from Rheox, Inc. under the trade name THIXCIN® R), organiccationic deposition polymer (e.g. Polyquaternium 10 available fromAmerchol Corp., guar hydroxypropyltrimonium chloride available asJAGUAR® C-17 from Rhodia Inc., and N-HANCE® polymer series commerciallyavailable from AQUALON), pH regulators (e.g. triethanolamine), anti-acnemedicaments, essential oils, sensates, pigments, colorants, pearlescentagents, interference pigments (e.g. such as those disclosed in U.S. Pat.No. 6,395,691 issued to Liang Sheng Tsaur, U.S. Pat. No. 6,645,511issued to Aronson et al., U.S. Pat. No. 6,759,376 issued to Zhang etal., U.S. Pat. No. 6,780,826 issued to Zhang et al.) particles (e.g.talc, kolin, mica, smectite clay, cellulose powder, polysiloxane,silicas, carbonates, titanium dioxide, polyethylene beads)hydrophobically modified non-platelet particles (e.g. hydrophobicallymodified titanium dioxide and other materials described in a commonlyowned, patent application published on Aug. 17, 2006 under PublicationNo. 2006/0182699A by Taylor, et al.) and combinations thereof. Otheroptional ingredients are most typically those materials approved for usein cosmetics and that are described in the CTFA Cosmetic IngredientHandbook, Second Edition, The Cosmetic, Toiletries, and FragranceAssociation, Inc. 1988, 1992.

V. Methods Related to Personal Care Articles and Personal CareCompositions Measuring Lather Volume

Lather volume of a personal skin care composition can be measured usinga graduated cylinder and a tumbling apparatus. A 1,000 ml graduatedcylinder is chosen which is marked in 10 ml increments and has a heightof 14.5 inches at the 1,000 ml mark from the inside of its base (forexample, Pyrex No. 2982). Distilled water (100 grams at 23° C.) is addedto the graduated cylinder. The cylinder is clamped in a rotating devicewhich clamps the cylinder with an axis of rotation that transects thecenter of the graduated cylinder. One gram of the total personalcleansing composition with specified cleansing phase to benefit phaseratio (0.75 g of the cleansing phase and 0.25 g of the benefit phase, or0.45 g of the cleansing phase and 0.55 g of the benefit phase) is addedinto the graduated cylinder and the cylinder is capped. The cylinder isrotated at a rate of 10 revolutions in about 20 seconds, and stopped ina vertical position to complete the first rotation sequence. A timer isset to allow 30 seconds for the lather thus generated to drain. After 30seconds of such drainage, the first lather volume is measured to thenearest 10 ml mark by recording the lather height in ml up from the base(including any water that has drained to the bottom on top of which thelather is floating).

If the top surface of the lather is uneven, the lowest height at whichit is possible to see halfway across the graduated cylinder is the firstlather volume (ml). If the lather is so coarse that a single or only afew foam cells (“bubbles”) reach across the entire cylinder, the heightat which at least 10 foam cells are required to fill the space is thefirst lather volume, also in ml up from the base. Foam cells larger thanone inch in any dimension, no matter where they occur, are designated asunfilled air instead of lather. Foam that collects on the top of thegraduated cylinder but does not drain is also incorporated in themeasurement if the foam on the top is in its own continuous layer, byadding the ml of foam collected there using a ruler to measure thicknessof the layer, to the ml of foam measured up from the base. The maximumfoam height is 1,000 ml (even if the total foam height exceeds the 1,000ml mark on the graduated cylinder). One minute after the first rotationis completed, a second rotation sequence is commenced which is identicalin speed and duration to the first rotation sequence. The second lathervolume is recorded in the same manner as the first, after the same 30seconds of drainage time. A third sequence is completed and the thirdlather volume is measured in the same manner, with the same pausebetween each for drainage and taking the measurement.

The lather result after each sequence is added together and the TotalLather Volume determined as the sum of the three measurements, in ml.The Flash Lather Volume is the result after the first rotation sequenceonly, in ml, i.e., the first lather volume. Compositions according tothe present invention perform significantly better in this test thansimilar compositions in conventional emulsion form.

Microcentrifugation Method:

The Microcentrifugation Method determines the variation of the percentof hydrophobic benefit material per dose in a package that comprises apersonal care article. As an overview, the personal care articles beingtested are dispensed in 10.0 mL sample sizes and these samples arecentrifuged. Centrifugation separates the sample size of personal carearticles into distinguishable layers. The first personal carecomposition, second personal care composition and third personal carecomposition have multiple distinguishable layers, for example amicrosphere layer, a surfactant layer, and a benefit layer thatcomprises hydrophobic benefit material, as shown in FIG. 2B and FIG. 2C.After centrifugation, the volume percentage of the benefit phase foreach sample is determined and plotted per dose of personal care articleto obtain the hydrophobic benefit material distribution profile of thepersonal care article throughout the product package.

TABLE 1 Description of Apparatus used in the Microcentrifugation MethodApparatus: Description: Micro-centrifuge VWR Galaxy 16DH 2 mLMicro-centrifuge VWR cat. No. 20170-170 clear tubes Disposable syringes1 mL, VWR cat. No. BD309602 Top Load balance Capable of weighing to 2decimal cases. Clear plastic cups 207 mL Solo Plastic cup Centrifugetube stand capacity to hold at least 24 tubes Electronic Digital Calipercapable of measuring 2 decimal cases in mm

To prepare the samples for a 295 mL package of a personal care article,label 24 clear plastic cups 1-24. Place cup 1 on top of balance andtare. Open package containing the personal care article, dispense 8.80g±0.50 g of product in cup 1, and record the weight of each sample.Repeat these instructions for all 24 cups, or for as many doses you canget from one package. If composition gets stuck in the package, tap thepackage in descending motion for four times.

Next, label 24 centrifuge tubes 1-24 doses. Then, mix the sample in cup1 well by stirring the sample with a stirrer by hand and then draw thesample into a syringe. Insert the syringe all the way to the bottom ofthe centrifuge tube. Slowly push the plunger as you withdraw the syringeform the centrifuge tube, making sure no air bubbles or gaps are formed.Check for air bubbles, if any air bubble is found tap the centrifugetube until sample fills the gaps left by the air bubbles. Load thesyringe with more sample of the product and bring the extremity of thesyringe to the top of the sample of the product that is inside thecentrifuge tube. Slowly push the plunger while withdrawing the syringefrom the centrifuge tube. Check for air bubbles, and eliminate them bytapping down the centrifuge tube. Fill the centrifuge tube to itsmaximum capacity with the sample of the product (i.e. all the way to therim), cap the centrifuge tube and place in the centrifuge tube rack.Repeat these steps until all 24 centrifuge tubes are filled.

Load the centrifuge as described in the manufacturer's instrumentoperation section of the instruction manual. Centrifuge each of thesamples for 15 minutes at 13,000 rpm. Once centrifugation is done,remove each centrifuge tube from centrifuge. Next, use a caliper tomeasure the length of benefit phase to 1/100 of mm. Record the length ofbenefit phase for each sample.

FIG. 2A is a diagram of the layers of a personal care composition aftercentrifugation. FIG. 2B and FIG. 2C are photographs that exemplify themeasurement of the benefit phase comprising hydrophobic benefit materialwithin in the centrifuged samples.

The volume of each dispensed sample is calculated by convert the weightof each sample to volume using product density (0.88 g/mL).

${Volume}_{({sample})} = \frac{Weight}{Density}$

The total volume dispensed is calculated by adding the volume of asample to the sum of the volumes of all previous samples. The percenthydrophobic benefit material is calculated using equation of calibrationcurve, below. In this equation, y=length of benefit layer and x=thepercentage hydrophobic benefit material in the sample.

$X = \frac{y + 3.0416}{0.3867}$

FIG. 3 depicts a calibration curve that was generated from 20 to 70%concentration of hydrophobic benefit material. This curve was used totransform mm of hydrophobic benefit material to percent of hydrophobicbenefit material in the composition.

Finally, plot the percentage of hydrophobic benefit material versus thetotal volume dispensed to obtain the hydrophobic benefit materialdistribution profile of the personal care article throughout thepackage.

Magnetic Resonance Imaging (MRI) Method:

The MRI Method is used to obtain images and quantitatively describe thebenefit distribution in 3-Dimension. The Instrument used is a 4.7TMagnex Scientific magnet with a 60 cm horizontal bore. The data iscollected using a Bruker 25 cm imaging coil and Bruker Paravision 3.0.2.The data is collected using a spin-echo pulse sequence, repetition timeof 1000 ms and echo time of 15 ms. Images were acquired of 32 of 2 mmthick slices were acquired along the flat surface of the package orbottle. The fields of view were 22 cm×10 cm with data size of 256×128,which results in in-plane pixel resolutions of 86 um×78 um.

The customized imaging analysis software used to analyze the MRI imagesis a Matlab based graphical user interface program, hereinafter referredto as “GUI program”. This GUI program was developed in order toquantitatively describe benefit layer distribution in 3-dimensions. TheGUI program sets thresholds based on MRI intensity to segment backgroundand/or void region, benefit region and surfactant region. Thedistribution of hydrophobic benefit material along the height and radialare summed and plotted as FIG. 4 and FIG. 5. FIG. 4 illustrates GUIbased analysis of personal care composition phase distribution along theradial dimensions of the package. FIG. 5 illustrates GUI based analysisof personal care composition phase distribution along the height of thepackage.

Dynamic Shipping Stability Method:

The dynamic shipping stability method is a simulated shipping test thatis conducted to illustrate the impact of the amount headspace on thedistribution profile of hydrophobic benefit material in a personal carearticle used in accordance with the present invention. The method isconducted on a vibration table, such as a MTS Vibration Table, availablefrom Lansmont TTV of Monterrey, Calif.

The method tests shipping cases of personal care articles. There are 6personal care articles or packages that are comprised within a shippingcase. The personal care articles are filled with inventive example Busing inventive filler profile B with various headspaces at 16%, 10% and3%, of the volume of the personal care article, respectively. Theshipping cases are submitted to simulated shipping conditions. Thetemperature of the shipping cases of personal care articles can bevaried to simulate shipping conditions from cold to warm climateregions.

Prior to submitting the shipping cases to simulated shipping conditions,MRI images of each personal care articled are obtained by the MRI methodat 25° C. Next, the shipping cases are subjected to simulated shippingconditions

There are four steps to induce the simulated shipping conditions:

Step 1: The shipping cases are dropped once at each of the sixorientations for a total of six times. The “six orientations,” of theshipping cases used are up, down, and on each of the four sides.

Step 2: The ASTM D4169 Truck Level 2 method is performed on the shippingcases in upright positions for three hours.

Step 3: The ASTM D4728 Truck method is performed with shipping cases atthe six orientations for thirty minutes for each orientation.

Step 4: The shipping cases are dropped once at each of the sixorientations for a total of six times.

After submitting the shipping cases to simulated shipping conditions,MRI images are taken for each personal care article by the MRI method at25° C.

The MRI images prior to and after simulated shipping conditions arevisually compared and graded of the shipping stability. The MRI imagesare compared on the amount of phase mixing, the presence of a zone ofhigh concentration of hydrophobic benefit material, the orientation ofthe concentration of hydrophobic benefit material medial to thedispensing orifice, the amount of void volume and an orientation of thevoid volume at the end proximal to the dispensing orifice. If aftersubmitting the shipping cases to simulated shipping conditions, the MRIimages that show an excessive amount of mixing, the absence of a zone ofhigh concentration of hydrophobic benefit material, an excessive amountof void volume and/or the volume is located medial or distal to thedispensing orifice; the personal care article would fail the dynamicstability shipping method. Conversely, if after submitting the shippingcases to simulated shipping conditions, the MRI images that show only aslight amount of mixing, the presence of a zone of high concentration ofhydrophobic benefit material which is located medial to the dispensingorifice, a small amount of void volume located proximal to thedispensing orifice; the personal care article would pass the dynamicstability shipping method.

The results of the dynamic shipping stability method are shown below inFIG. 6A, FIG. 6B and FIG. 6C. As shown in FIG. 6A, the packages with 16%headspace shows extensive co-mixing of the two phases and thus, failedthe shipping dynamic shipping stability method. As shown in FIG. 6B, thepackages with 10% headspace shows improved dynamic shipping stabilitymethod as the zone of high concentration of hydrophobic benefit materialis still apparent in the MRI image. As shown in FIG. 6C, the packageswith 3% headspace shows the best shipping stability as the variableconcentrations of hydrophobic benefit material is maintained aftershipping protocol.

Ultracentrifugation Method:

The Ultracentrifugation Method is used to determine the percent of astructured domain or an opaque structured domain that is present in apersonal care composition that comprises a surfactant phase or asurfactant component. The method involves the separation of acomposition by ultracentrifugation into separate but distinguishablelayers. The first personal care composition, second personal carecomposition and third personal care composition have multipledistinguishable layers, for example a non-structured surfactant layer, astructured surfactant layer, and a benefit layer.

First, dispense about 4 grams of personal care composition into BeckmanCentrifuge Tube (11×60 mm). Next, place the centrifuge tubes in anUltracentrifuge (Beckman Model L8-M or equivalent) and ultracentrifugeusing the following conditions: 50,000 rpm, 18 hours, and 25° C.

After ultracentrifuging for 18 hours, determine the relative phasevolume by measuring the height of each layer visually using anElectronic Digital Caliper (within 0.01 mm). First, the total height ismeasured as H_(a) which includes all materials in the ultracentrifugetube. Second, the height of the benefit layer is measured as H_(b).Third, the structured surfactant layer is measured as H. The benefitlayer is determined by its low moisture content (less than 10% water asmeasured by Karl Fischer Titration). It generally presents at the top ofthe centrifuge tube. The total surfactant layer height (H_(s)) can becalculated by this equation:

H _(s) =H _(a) −H _(b)

The structured surfactant layer components may comprise several layersor a single layer. Upon ultracentrifugation, there is generally anisotropic layer at the bottom or next to the bottom of theultracentrifuge tube. This clear isotropic layer typically representsthe non-structured micellar surfactant layer. The layers above theisotropic phase generally comprise higher surfactant concentration withhigher ordered structures (such as liquid crystals). These structuredlayers are sometimes opaque to naked eyes, or translucent, or clear.There is generally a distinct phase boundary between the structuredlayer and the non-structured isotropic layer. The physical nature of thestructured surfactant layers can be determined through microscopy underpolarized light. The structured surfactant layers typically exhibitdistinctive texture under polarized light. Another method forcharacterizing the structured surfactant layer is to use X-raydiffraction technique. Structured surfactant layer display multiplelines that are often associated primarily with the long spacings of theliquid crystal structure. There may be several structured layerspresent, so that H_(c) is the sum of the individual structured layers.If a coacervate phase or any type of polymer-surfactant phase ispresent, it is considered a structured phase.

Finally, the structured domain volume ratio is calculated as follows:

Structured Domain Volume Ratio=H _(c) /H _(s)*100%

If there is no benefit phase present, use the total height as thesurfactant layer height, H_(s)=H_(a).

Yield Stress and Zero Shear Viscosity Method:

The Yield Stress and Zero Shear Viscosity of a composition containedwithin a zone, can be measured either prior to combining the phases in acomposition, or after combining the phases in a composition byseparating the phases by suitable physical separation means, such ascentrifugation, pipetting, cutting away mechanically, rinsing,filtering, or other separation means. In the case of testing from aproduct package, two zones can be selected from the package thatcontains at least two compositions that contain separate hydrophobicbenefit material concentrations. In order to separate the zones, theproduct can be frozen at a temperature of at least −20° C. for a periodof at least 24 hours. The zones are then cut using a cutting implementsuch as a bandsaw. The cut portions are collected separately and allowedequilibrate to ambient conditions.

A controlled stress rheometer, such as a TA Instruments AR2000Rheometer, is used to determine the Yield Stress and Zero ShearViscosity. The determination is performed at 25° C. with the 4 cmdiameter parallel plate measuring system and a 1 mm gap. The geometryhas a shear stress factor of 79580 m⁻³ to convert torque obtained tostress. Serrated plates can be used to obtain consistent results whenslip occurs.

First a sample of the composition is obtained and placed in position onthe rheometer base plate, the measurement geometry (upper plate) movinginto position 1 mm above the base plate. Excess phase at the geometryedge is removed by scraping after locking the geometry. If the phasecomprises particles discernible to the eye or by feel (beads, e.g.)which are larger than about 150 microns in number average diameter, thegap setting between the base plate and upper plate is increased to thesmaller of 4 mm or 8-fold the diameter of the 95^(th) volume percentileparticle diameter. If a phase has any particle larger than 5 mm in anydimension, the particles are removed prior to the measurement.

The determination is performed via the programmed application of acontinuous shear stress ramp from 0.1 Pa to 1,000 Pa over a timeinterval of 4 minutes using a logarithmic progression, i.e., measurementpoints evenly spaced on a logarithmic scale. Thirty (30) measurementpoints per decade of stress increase are obtained. Stress, strain andviscosity are recorded. If the measurement result is incomplete, forexample if material flows from the gap, results obtained are evaluatedand incomplete data points excluded. The Yield Stress is determined asfollows. Stress (Pa) and strain (unitless) data are transformed bytaking their logarithms (base 10). Log(stress) is graphed vs.log(strain) for only the data obtained between a stress of 0.2 Pa and2.0 Pa, about 30 points. If the viscosity at a stress of 1 Pa is lessthan 500 Pa-sec but greater than 75 Pa-sec, then log(stress) is graphedvs. log(strain) for only the data between 0.2 Pa and 1.0 Pa, and thefollowing mathematical procedure is followed. If the viscosity at astress of 1 Pa is less than 75 Pa-sec, the zero shear viscosity is themedian of the 4 highest viscosity values (i.e., individual points)obtained in the test, the yield stress is zero, and the followingmathematical procedure is not used. The mathematical procedure is asfollows. A straight line least squares regression is performed on theresults using the logarithmically transformed data in the indicatedstress region, an equation being obtained of the form:

Log(strain)=m*Log(stress)+b  (1)

Using the regression obtained, for each stress value (i.e., individualpoint) in the determination between 0.1 and 1,000 Pa, a predicted valueof log(strain) is obtained using the coefficients m and b obtained, andthe actual stress, using Equation (1). From the predicted log(strain), apredicted strain at each stress is obtained by taking the antilog (i.e.,10^(x) for each x). The predicted strain is compared to the actualstrain at each measurement point to obtain a % variation at each point,using Equation (2).

% variation=100*(measured strain−predicted strain)/measured strain  (2)

The Yield Stress is the first stress (Pa) at which % variation exceeds10% and subsequent (higher) stresses result in even greater variationthan 10% due to the onset of flow or deformation of the structure. TheZero Shear Viscosity is obtained by taking a first median value ofviscosity in Pascal-seconds (Pa-sec) for viscosity data obtained betweenand including 0.1 Pa and the Yield Stress. After taking the first medianviscosity, all viscosity values greater than 5-fold the first medianvalue and less than 0.2× the median value are excluded, and a secondmedian viscosity value is obtained of the same viscosity data, excludingthe indicated data points. The second median viscosity so obtained isthe Zero Shear Viscosity.

VI. Method of Manufacture

In one embodiment, the personal care articles of the present inventionare manufactured by a dual phase filler. The dual phase filler isassociated with storage vessels, a combiner, a blender and nozzle forfilling multiple personal care compositions. An example of a dual phasefiller and associated software is manufactured by Antonio MengibarPackaging Machinery of Barcelona, Spain. The surfactant phase andbenefit phase of the personal care compositions are stored in separatestorage vessel; each vessel equipped with a pump and a hose assembly. Aprogrammed filler profile of the dual-phase filler controls the pumpingof specific ratios of the two phases of the personal care compositionswhich result in the zones within a package. The two phases of thepersonal care compositions are pumped from the storage tanks into acombiner where the two phases are combined. After the phases arecombined; they are mixed in a blender. From the blender, the resultantproduct is pumped via a hose into a single nozzle. The nozzle is placedinto a container and fills a product package with a single resultingproduct. In some embodiments, the resultant product exhibits a distinctpattern of the phases which are visually distinct. In other embodiments,the resultant product exhibits a uniform appearance without a pattern.If a pattern is present, the pattern is selected from the groupconsisting of striped, marbled, geometric, and combinations thereof.

In another embodiment, the personal care compositions used in accordancewith the present invention are manufactured according to the methoddisclosed in U.S. patent application Ser. No. 10/837,214 Publication No.2004/0219119 A1 entitled “Visually distinctive multiple liquid phasecompositions” filed by Wei et al. on Apr. 30, 2004, published on Nov.18, 2004. Alternatively, it may be effective to combine toothpaste-tubefilling technology with a spinning stage design. In still anotherembodiment, the personal care compositions are prepared by the methodand apparatus as disclosed in U.S. Pat. No. 6,213,166 issued to Thibiantet al. on Apr. 10, 2001. The method and apparatus allow two or morecompositions to be filled with a spiral configuration into a singleproduct package. The method requires that at least two nozzles beemployed to fill the compositions into a package. The package is placedon a moving stage and spun as the composition is introduced into thepackage.

Non-limiting examples of the personal care compositions, ratios ofphases and filler profiles are disclosed in the examples below.

VII. Composition and Articles Examples Example 1 Exemplary Personal CareArticles

Table 2 shows non-limiting examples of the personal care articles of thepresent invention and a comparative example. These personal carearticles are made and filled in a single chamber package. The personalcare compositions used in accordance with the present invention comprisevarious concentrations of hydrophobic benefit material through out thepackage. These personal care compositions used in accordance with thepresent invention are filled in a package within multiples zones. Thecomparative example comprises uniform concentration of hydrophobicbenefit material through out the package.

TABLE 2 Examples of the Present Invention and Comparative ExampleInventive Inventive Comparative Example A Example B Example C SurfactantPhase Composition Sodium 4.9 4.9 4.9 Lauroamphoacetate^(1.) SodiumTrideceth 8.4 8.4 8.4 Sulfate^(2.) Sodium Lauryl Sulfate 8.4 8.4 8.4Trideceth-3^(3.) 2.0 2.0 2.0 Sodium Chloride 4.75 4.75 4.75 Guarhydroxypropyl- 0.6 0.6 0.6 trimonium chloride^(4.)Polyethyleneoxide^(5.) 0.15 0.15 0.15 Xanthan gum^(6.) 0.2 0.2 0.2Hollow microspheres^(7.) 0.36 0.3 0.3 Methyl chloro 0.0005 0.0005 0.0005isothiazolinone and methyl isothiazolinone^(8.) EDTA^(9.) 0.15 0.15 0.15Sodium Benzoate 0.2 0.2 0.2 Citric Acid, titrate pH = 5.7 ± 0.2 pH = 5.7± 0.2 pH = 5.7 ± 0.2 Perfume 1.3 1.3 1.3 Water Q.S. Q.S. Q.S. BenefitPhase Composition Petrolatum^(10.) 70 70 70 Mineral Oil^(11.) 30 30 30Filler Profile Inventive Inventive Comparative Profile A Profile BProfile C ^(1.)available from Cognis Chemical Corp. ^(2.)sulfanatedto >95% sulfate from ICONOL ® TDA-3 available from BASF Corp.,^(3.)ICONOL ® TDA-3 available from BASF Corp., ^(4.)N-HANCE ® 3196Polymer from Aqualon of Wilmington, DE, ^(5.)POLYOX ™ WSR-301 availablefrom DOW ® Chemical Corp., ^(6.)KELTRO ™ 1000 available from CP Kelco,^(7.)EXPANCEL ® microspheres available from 091 WE40 d24, Akzo Nobel,^(8.)KATHON ® CG available for Rohm & Haas, ^(9.)DISSOLVINE ® NA 2xavailable from Akzo Nobel, ^(10.)G2218 petrolatum from Sonneborn,^(11.)HYDROBRITE ® 1000 White Mineral Oil available from Sonneborn.

The compositions described above can be prepared by conventionalformulation and mixing techniques. The surfactant phase composition ismade by first preparing a citric acid premix and then a polymer pre-mix.The citric acid premix is prepared by adding citric acid into water at aratio of 1:3. The polymer premix is prepared by adding polyethyleneoxideand xanthan gum into trideceth-3. The following ingredients are thenadded into the main mixing vessel in the following sequence withagitation: water, guar hydroxypropyltrimonium chloride, hollowmicrospheres, sodium lauroamphoacetate, sodium trideceth sulfate, sodiumlauryl sulfate, sodium chloride, sodium benzoate, and disodium EDTA. Thecitric acid premix is added into the main mixing vessel and the pH ofthe composition is adjusted to 5.7±0.2. The polymer premix is next addedinto the main mixing vessel with continuous agitation. Perfume andmethyl chloro isothiazolinone and methyl isothiazolinone are added whilecontinuing the agitation until the composition is homogeneous. Theresultant surfactant phase composition is fed into the dual-phase fillerthrough a hose-assembly.

The benefit phase composition is prepared by first adding petrolatuminto a mixing vessel. The mixing vessel has been heated to 82.2° C.Mineral oil is added into the mixing vessel with agitation. The benefitphase composition is cooled to 44° C. through a scraped-wallheat-exchanger, such as that manufactured by Waukesha Cherry-Burrell,Delavan, Wis. After cooling, the resultant benefit phase composition isfed into the dual-phase filler through a second hose-assembly.

The filler profiles A, B and C are examples of filling programs thatspecify the ratios of the surfactant and benefit phases within packagesfilled by a dual phase filler. Filler profiles A and B specify variablehydrophobic benefit material concentrations throughout the zones of thepersonal care articles of the present invention. Whereas filler profileC specifies uniform hydrophobic benefit material concentrations in theresultant personal care article within the package.

TABLE 3 Dual Phase Filler Profiles for Example A and B Filler Profile AFiller Profile B Benefit Sur- Benefit Sur- Dose Material factant DoseMaterial factant Step (mL) % % Step (mL) % % 1 33.6 24 76 1 33.2 30 70 261.4 42 58 2 61.7 50 50 3 70.6 52 48 3 71.2 60 40 4 104.2 63 37 4 104.470 30 5 133.2 63 37 5 132.9 60 40 6 155.2 52 48 6 154.7 50 50 7 174.9 4258 7 194.6 40 60 8 194.5 32 68 8 223.1 20 80 9 223.5 15 85 9 248.7 10 9010 249.0 7 93 10 280.0 20 80 11 280.2 15 85 11 289.5 30 70 12 289.5 2773 — — — —

TABLE 4 Dual Phase Filler Profiles for Example C Filler Profile C StepDose (mL) Benefit Material % Surfactant % 1 11 45 55 2 20 45 55 3 35 4555 4 52 45 55 5 75 45 55 6 108 45 55 7 148 45 55 8 188 45 55 9 229 45 5510 265 45 55 11 280 45 55

FIG. 7 depicts MRI images that illustrate the surfactant and hydrophobicbenefit material distribution in a package of examples A, B and C. Theseimages were taken by the MRI Method, described in detail in the TestMethods above. As shown in FIG. 7, the comparative example C shows auniform hydrophobic benefit material distribution throughout thepackage. Inventive examples A and B, in FIG. 7 show a variablehydrophobic benefit material distribution profile with higher benefitzones are highlighted with arrows.

FIG. 8 is a chart of the hydrophobic benefit material distribution inexamples A and B of the present invention. The Micro centrifugationMethod, described in detail in the Test Methods above, was used toquantify the hydrophobic benefit material distribution in the inventiveexamples A and B. Profile A and profile B, shown in FIG. 8 clearly showa variable benefit distribution from the beginning, middle, and end ofthe dispensing.

The dimensions and values disclosed herein are not to be understood asbeing strictly limited to the exact numerical values recited. Instead,unless otherwise specified, each such dimension is intended to mean boththe recited value and a functionally equivalent range surrounding thatvalue. For example, a dimension disclosed as “40 mm” is intended to mean“about 40 mm.”

All documents cited in the Detailed Description of the Invention are, inrelevant part, incorporated herein by reference; the citation of anydocument is not to be construed as an admission that it is prior artwith respect to the present invention. To the extent that any meaning ordefinition of a term in this document conflicts with any meaning ordefinition of the same term in a document incorporated by reference, themeaning or definition assigned to that term in this document shallgovern.

While particular embodiments of the present invention have beenillustrated and described, it would be obvious to those skilled in theart that various other changes and modifications can be made withoutdeparting from the spirit and scope of the invention. It is thereforeintended to cover in the appended claims all such changes andmodifications that are within the scope of this invention.

1. A method for providing a personal skin care article with an optimized user experience profile, the method comprising: identifying a target population, developing a population profile with respect to a rinse-off personal care composition used for cleansing and moisturizing comprising the steps of determining the population preferences for maximum amount of hydrophobic benefit agent, and determining the population preferences for lather volume, lather texture, and lathering speed, composition thickness, color, translucence, opalescence, and scent formulating a personal care composition reflecting a population profile, wherein the composition comprises varying ratios of a lathering agent to a hydrophobic benefit agent, configuring a delivery article adapted to dispense the composition in discrete aliquots of approximately equal volume, and adapted to contain the composition so as to dispense the composition in phases comprising at least: a first phase comprising a first ratio of the varying ratios of lathering agent to hydrophobic benefit agent, a second phase comprising a second ratio of the varying ratios of lathering agent to hydrophobic benefit agent that is different than the first ratio; manufacturing the composition for the target population; providing the composition in the delivery article.
 2. The method according to claim 1, wherein the steps are repeated for a different target population.
 3. The method according to claim 1, comprising a third phase comprising a third ratio of the varying ratios of lathering agent to hydrophobic benefit agent that is different than the second ratio.
 4. The method according to claim 3, wherein the ratio in the second phase is lower than the ratio in the first phase, and wherein the ratio in the third phase is the same as or lower than the ratio in the first phase.
 5. The method according to claim 4, wherein the ratios of lathering agent to hydrophobic benefit agent vary continuously from the start of the first phase through the end of the third phase.
 6. The method according to claim 4, wherein the ratios of lathering agent to hydrophobic benefit agent vary continuously through at least a portion of the phases.
 7. The method according to claim 4, wherein the ratio of lathering agent to hydrophobic benefit agent is at a maximum of about 75:25 in the first phase, and the ratio of lathering agent to hydrophobic benefit agent is at a minimum of about 45:55 in the second phase, and the ratio of lathering agent to hydrophobic benefit agent is at a maximum of about 75:25 in the third phase.
 8. The method according to claim 4, wherein the ratio of lathering agent to hydrophobic benefit agent is at a maximum of about 70:30 in the first phase, and the ratio of lathering agent to hydrophobic benefit agent is at a minimum of about 45:55 in the second phase, and the ratio of lathering agent to hydrophobic benefit agent is at a maximum of about 80:20 in the third phase.
 9. The method according to claim 4, wherein the ratio of lathering agent to hydrophobic benefit agent is at a maximum of about 75:25 in the first phase, and the ratio of lathering agent to hydrophobic benefit agent is at a minimum of about 45:55 in the second phase, and the ratio of lathering agent to hydrophobic benefit agent is at a maximum of about 75:25 in the third phase.
 10. The method according to claim 4, wherein the ratio of lathering agent to hydrophobic benefit agent is at a maximum in the range from about 50:50 to 90:10 in the first phase, and the ratio of lathering agent to hydrophobic benefit agent is at a minimum in the range from about 10:90 to 50:50 in the second phase, and the ratio of lathering agent to hydrophobic benefit agent is at a maximum in the range from about 50:50 to 90:10 in the third phase.
 11. The method according to claim 1, wherein the lather volume is greater than 800 ml to 1500 ml by the cylinder lather method.
 12. The method according to claim 11, wherein the lather volume is greater than 800 ml.
 13. The method according to claim 11, wherein the lather volume is greater than 1000 ml.
 14. The method according to claim 11, wherein the lather volume is greater than 1500 ml. 